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Mycoplasma bovis can be the bane of a farmer’s existence. As one of the most important 
members of the bovine Mollicutes, it causes a multitude of diseases, most notable of which 
are mastitis, pneumonia and arthritis in adult cows and pneumonia, arthritis and otitis in 
calves. M. bovis infections have a tremendous adverse impact on the economic output of 
the farm, its antimicrobial use and the welfare of the cattle affected. Although the 
pathogen is present in most countries worldwide, prevalence differs a lot. Introduction 
into farms is generally caused by the purchase of a (sub)clinically infected animal, but a 
multitude of other possible ways of introduction have been suggested in the past, which 
need to be evaluated in the effort to keep herds disease-free.  
Due to the chronic nature of mycoplasmal disease and the presence of subclinical 
shedders, detecting the infection can be difficult. Treatment is often disappointing as well, 
due to M. bovis’ innate resistance to multiple antimicrobials and chronicity linked to 
several virulence factors. Decreasing susceptibility to antimicrobial agents has been 
reported as well, with country specific differences. Treatment failure happens so often, 
that for certain M. bovis caused diseases such as mastitis the current advice is to cull all 
affected animals.  
Since effective treatment is difficult, focus should be on disease prevention. Unfortunately, 
the design of a M. bovis vaccine appears to be difficult, hence its absence in Europe as a 
tool to control M. bovis infections. Through epidemiological research, certain risk factors 
such as purchase of replacement animals and insufficient milking hygiene have been 
identified. However, a lot more research is needed to fully understand the way M. bovis 
can enter herds and migrate throughout the herd, before effective control and prevention 
programs can be developed.  
This thesis aimed to fill in some of the gaps still present in our epidemiological knowledge 
of M. bovis, to aid in the development of new, better preventive measures to contain the 
ongoing spread of M. bovis. 
 
 












Mycoplasma bovis: an overview 
1. ETIOLOGY AND CHARACTERISTICS 
Mycoplasma bovis, previously called Mycoplasma agalactiae var. bovis or Mycoplasma 
bovimastitidis, was probably first described in 1954 as a case of bovine pneumonia 
(Carter, 1954; Jasper et al., 1974b; Askaa and Erno, 1976; Pfützner and Sachse, 1996). The 
first isolation out of bovine mastitis followed 8 years later, in 1962 (Hale et al., 1962). In 
the following decades, M. bovis has spread throughout the world (ter Laak et al., 1992; 
Spergser et al., 2013; Aebi et al., 2015). Because of the increasing movement of cattle 
across countries, only a few countries managed to steer clear of the bacterium (Reeve-
Johnson, 1999). In July 2017, M. bovis was found in New Zealand as well, one of the last 
remaining M. bovis free countries until then (Ministry for Primary Industries, 2017).  
The economic impact of M. bovis caused diseases is hard to encompass. Due to the 
chronicity of infections with this bacterium the total loss of weight gain, feed conversion, 
therapy costs and man hours is often unknown (Caswell and Archambault, 2008). Purely 
based on loss of carcass value and decreased weight gain, the cost for the US beef industry 
alone has been estimated to lay around 32 million dollars a year in 1999, which would be 
around 48 million dollars in 2018 accounting for inflation (Rosengarten and Citti, 1999). 
The decreased weight gain can be up to 800g for each week of pneumonia in the first three 
months of age (Reeve-Johnson, 1999). When looking at M. bovis mastitis related losses in 
the US dairy industry, this cost goes up to 108 million dollars a year (136 million when 
accounting for inflation) (Rosengarten and Citti, 1999). In 2003, the yearly economic 
losses due to Bovine Respiratory Disease (BRD) and related illnesses across Europe were 
estimated to be 576 million euros (733 million euros when accounting for inflation), of 
which 25% - 33% could be attributed to M. bovis (Nicholas and Ayling, 2003). Of course, 
next to the economic costs, the welfare impact of the disease should not be 
underestimated, as M. bovis is often the cause of chronic illness with less than optimal 
response to treatment (Maunsell et al., 2011).  
M. bovis is part of the genus Mycoplasma within the Mycoplasmacetae, which is a family 
within the class Mollicutes. Mollicutes (literally translated as “soft skinned”) are a specific 
class of bacteria, unique because of their lack of a cell wall. Originally stemming from a 
gram-positive lineage, they are among the smallest self-replicating organisms (200-300 
nm), with a very small genome as well (Razin, 1992; Caswell and Archambault, 2008). 




Mycoplasmataceae are mainly parasitic in nature with, so far, around 180 known species 
infecting mammals, reptiles, fish, plants and arthropods (Razin et al., 1998). The different 
species generally are rather strict tissue- and host specific, but can on occasion cross to 
other tissues or hosts (Madoff et al., 1979; Razin et al., 1998; Pitcher and Nicholas, 2005). 
Next to M. bovis, several other species of Mycoplasma are known cattle pathogens. 
Mycoplasma mycoides subsp. mycoides is the most pathogenic among them, as the cause of 
contagious bovine pleuropneumonia, the only bacterial disease on the former list A 
diseases of the Office International des Epizooties (Nicholas and Ayling, 2003). Next to 
Mycoplasma, there is one other genus of Mycoplasmataceae of importance for cattle, 
namely Ureaplasma, and one other family of importance in the Mollicutes class, the 
Acholeplasmaceae (Erno, 1987). An overview of the Mycoplasma, Ureaplasma and 
Acholeplasma species currently assumed to cause disease in cattle is shown in Table 1.  
Geographical distribution of certain Mycoplasma species is possible: in the United States, 
only half of the Mycoplasma mastitis cases are caused by M. bovis, the remainder being 
caused by M. californicum, M. bovigenitalium, M. alkalescens and M. canadense. In Europe 
however, almost all reports list M. bovis as the main cause of Mycoplasma mastitis, though 
one of the most commonly used PCR mastitis tests (PathoProof™, Thermo Fisher 
Scientific, MA, USA) only tests for this species specifically (other Mycoplasma are 
grouped), possibly resulting in the under diagnosis of other Mycoplasma species in this 
part of the world (Fox, 2012; Nicholas et al., 2016). Even though M. bovis is primarily a 
cause of disease in cattle, it is also known to cause disease in other hosts on occasion, and 
could potentially spread from these hosts to other susceptible cattle again (Pfützner and 
Sachse, 1996). In buffaloes and bison, M. bovis is especially feared because of the high 
mortality associated with herd outbreaks (Bras et al., 2016; Calcutt et al., 2018). In 
Austria, M. bovis was isolated from pigs that were housed on the same pasture and stables 
as a cattle herd which was experiencing a dramatic primary outbreak of M. bovis 
associated diseases. The pigs showed clinical respiratory disease, with conjunctivitis, 
nasal discharge and coughing (Spergser et al., 2013). Reports of isolation of M. bovis out 
of (mainly) respiratory infections are available for sheep, goats, deer and poultry as well 
(Damassa et al., 1992; Dyer et al., 2004; Ongor et al., 2008; Kumar et al., 2012). M. bovis 
can act as a zoonosis, primarily in immunosuppressive patients, and has on occasion 
caused systemic illness (Madoff et al., 1979; Pitcher and Nicholas, 2005). 





Table 1: Mycoplasma (M.) , Ureaplasma (U.) and Acholeplasma (A.) species with a predilection for cattle 




A. axanthum Mastitis, possible pneumonia ? 
Pfützner et al., 1979, Reeve-
Johnson, 1999 
A. laidlawii Mastitis, reproductive tract lesions ? 
Pfützner et al., 1979, Doig, 1981, 
Kirkbride, 1987 
A. modicum Possible pneumonia ? Reeve-Johnson, 1999 
M. alkalescens Mastitis, arthritis, pneumonia Yes 
Bennett and Jasper, 1978, Jasper, 
1980, Thomas et al., 2003, 
Kokotovic et al., 2007 
M. alvi 
Isolated out of intestinal and urogenital tract, 
importance unknown 
? 
Gourlay et al., 1977, Nicholas et al., 
2008 
M. arginini Mastitis, pneumonia Yes 
Muenster et al., 1979, González and 
Wilson, 2003 
M. bovigenitalium 
Genital infections both genders, mastitis, 
pneumonia 
? 
Gourlay et al., 1979, Jasper, 1980, 
Fox, 2012 
M. bovirhinis 
Often found, relevance questionable, possible 
involvement in pneumonia and mastitis 
Yes 
Muenster et al., 1979, Thomas et 
al., 2003, Fox et al., 2005 
M. bovis 
Pneumonia, mastitis, otitis, arthritis, 
meningitis, infectious keratoconjunctivitis, 
oophoritis, salpingitis, abscesses, abortion, 
polyserositis, infertility, pericarditis 
Yes 
Hirth et al., 1966, Kinde et al., 1993, 
Adegboye et al., 1996, Pfützner and 
Sachse, 1996,  Thomas et al., 2003, 
Gagea et al., 2006, Nicholas et al., 
2008 
M. bovoculi Infectious keratoconjunctivitis, mastitis ? Fox et al., 2005, Schnee et al., 2015 
M. californicum Mastitis, pneumonia, arthritis ? 
Jasper, 1980, Hewicker-Trautwein 
et al., 2002, Fox, 2012 
M. canadense Mastitis ? González and Wilson, 2003 
M. canis 
Pneumonia, mastitis, part of the microflora of 
the bovine respiratory tract 
Yes 
ter Laak et al., 1993, Thomas et al., 
2003, Fox et al., 2005, Nicholas et 
al., 2008 
M. dispar Pneumonia, immunosuppression, mastitis Yes 
Gourlay et al., 1979, Howard et al., 
1987, Thomas et al., 2003, Fox et 




Infectious anemia (Haemoplasma), hock 
swelling, fever, transplacental infection with 
possible abortion 
? 
Ayling et al., 2012, Girotto-Soares 
et al., 2016 
M. mycoides subsp. 
mycoides 
Contagious bovine pleuropneumonia: 
Pneumonia, fever, arthritis, death 
No 
Provost et al., 1987, Nicholas et al., 
2008 
M. leachii sp. nov. 
(Leach’s M. species 
group 7) 
Mastitis, arthritis, abortion, pneumonia ? Hum et al., 2000, Chang et al., 2011 
M. verecundum Conjunctivitis ? Gourlay et al., 1974 
M. wenyonii Haemoplasma; edema, fever Yes 
Montes et al., 1994, Strugnell and 
McAuliffe, 2012, DGZ, 2015 
U. diversum Genital infections Yes 
Kirkbride, 1987, Thomas et al., 
2003 





Mycoplasma bovis has, just like many other Mycoplasma species, a tight association with 
the host cells (Caswell et al., 2010). Probably as a consequence of the small genome of said 
Mycoplasma, it has caused them to depend on the nutrition and growth of host cells to 
ensure their survival (Maunsell and Donovan, 2009).  
Surface adhesion is, in part, mediated by so called variable surface lipoproteins (Vsp) 
(Sachse et al., 2000; Caswell et al., 2010). Laying on the surface of M. bovis plasma 
membrane, in total, 13 different Vsps have been identified, all of them having antigenic 
properties stimulating the hosts immune response (Lysnyansky et al., 2001; Perez-Casal 
et al., 2017). Thanks to genes that allow variable (uncoordinated) expression of these 
Vsps (ON or OFF), M. bovis is capable of rapid variability in the antigenic expression of 
their outer cell membrane proteins, effectively evading the hosts antibodies (Razin et al., 
1998; González and Wilson, 2003). Antibody expression to a specific Vsp can even result 
in the selection of variant mycoplasmas expressing OFF in that Vsp (González and Wilson, 
2003). Furthermore, due to different expression of proteins, Vsps will have size variations 
as well, further resulting in variability of the antigenic expression (Lysnyansky et al., 
2001). Different M. bovis strains can have different versions of the Vsp encoding gene 
complex, leading to a multitude of phenotypic variations (Razin et al., 1998; Perez-Casal 
et al., 2017). Next to the Vsps, also other membrane proteins have been found, providing 
even more surface membrane diversification (González and Wilson, 2003). The rapidly 
changing and diverse expression of these antigens on the plasma membrane is suspected 
to play a major role in the difficulty of producing large scale effective vaccines against M. 
bovis (Perez-Casal et al., 2017). 
Infection with M. bovis evokes a robust localized and systemic immune response (Caswell 
et al., 2010). In serum, an IgG and IgM reaction can be seen, whereas in nasal and lung 
fluids the reaction is mainly IgA based (Caswell et al., 2010). The IgG immune response 
seems to be mainly composed of IgG1, whereas IgG2 usually has the superior opsonin 
activity, possibly contributing to the chronic nature of M. bovis infections (Vanden Bush 
and Rosenbusch, 2003). Furthermore, the immune response is also skewed towards T 
helper 2 cells, with an inhibition of the Th1 response which would provide a superior 
immunity (Vanden Bush and Rosenbusch, 2003). 




Long term survival of M. bovis in necrotic tissue has been described, in the presence of 
phagocytic cells such as macrophages and neutrophils (Kleinschmidt et al., 2013). This 
could be an indication that the chronic persistence of M. bovis is also due to a resistance 
to phagocytosis (Kleinschmidt et al., 2013). Next to this, M. bovis was shown to suppress 
lymphocyte proliferation and inhibit the oxidative burst of neutrophils, further 
weakening the immune response (Thomas et al., 1991; Srikumaran et al., 2007). M. bovis 
has been shown to reside intracellularly in peripheral blood mononuclear cells (B cells, T 
cells, monocytes and others) and erythrocytes, possibly using these circulating blood cells 
as a means of transport throughout the hosts body and immunoevasion (van der Merwe 
et al., 2010). M. bovis was able to invade and multiply in embryonic turbinate cells as well, 
further demonstrating the possibility of immunoevasion and avoidance of antimicrobials 
by residing intracellularly (Burki et al., 2015).  
M. bovis is able to activate complement and increase vascular permeability by the 
production of inflammatory substances such as H2O2 and toxins (Geary et al., 1981; Khan 
et al., 2005; van der Merwe et al., 2010). H2O2 production can cause contact-cytotoxicity 
to epithelial cells in theory (Bürki et al., 2015), but a study by Schott et al. (2014) failed to 
detect a difference in H2O2 expression between caseonecrotic pneumonia, other types of 
pneumonia and non-pneumonic lungs affected by M. bovis. They did detect 
immunohistological markers for lipid peroxidation and tyrosine nitration, which can 
contribute to the caseonecrotic lesions typical for M. bovis pneumonia and -arthritis (Devi 
et al., 2014; Schott et al., 2014). It has been speculated that the aforementioned 
domination of the (less effective) Th2 response is the result of oxygen free radical 
production by M. bovis (Schott et al., 2014). 
M. bovis has the capacity to produce a biofilm, making it possible for the bacterium to 
survive in the environment for longer, while withstanding the stress of heat or desiccation 
(McAuliffe et al., 2006). There is a large amount of strain variability, with some M. bovis 
strains barely being able to form a biofilm or adhere to a surface compared to others, 
seemingly correlated to the expression of certain Vsps (McAuliffe et al., 2006). It was 
shown possible for M. bovis to remain viable in the environment for months at low 
temperatures, and weeks at room temperature on a variety of substrates (table 2) 
(Pfützner, 1984). The formation of a biofilm does not significantly influence the minimum 
inhibitory concentration (MIC) of antimicrobials to M. bovis compared to planktonic 




strains (McAuliffe et al., 2006). However, it can increase the amount of self-induced 
damage to host tissues, by attracting and activating phagocytes while being protected 
from phagocytosis, inducing the phagocytes to release more lysosomal enzymes, reactive 
oxygen and nitrogen (Bürki et al., 2015).  
 
Figure 1: Mycoplasma bovis predilection sites 
This figure portrays the most common predilection sites of M. bovis: nares, tonsillae, eyes, Bulla 
tympanica, meninges, lungs, udder, joints, genital area and hematological spread  




3. PATHOLOGY AND DISEASE COURSE 
M. bovis is chameleon-like, being able to change its behavior to cause a variety of clinical 
symptoms, grouped under the term “mycoplasmosis”. Most commonly, mastitis and 
arthritis are observed in adult cattle, and pneumonia, arthritis and otitis in calves, 
combined with general signs of an infection, such as fever, depression and anorexia. Since 
M. bovis can spread hematogenously, symptoms in affected animals can vary and change 
in time (Rosengarten and Citti, 1999). The possibility of strains having a predilection for 
specific diseases has been suggested but more research is warranted on this topic 
(McAuliffe et al., 2004). An overview of the most common M. bovis predilection sites is 
shown in Figure 1.  
3.1. MASTITIS 
In adult cattle, M. bovis is mainly feared as a cause of mastitis (Figure 2). Highly contagious, 
it is a major cause of reduced welfare and milk production, especially in large dairy herds 
(Nicholas et al., 2016). In European countries, Mycoplasma mastitis is seen as a rising 
problem, though this could also be partially related to a lack of targeted searches in the 
past, as M. bovis is usually overgrown on standard bacterial culture (Nicholas et al., 2016).  
Mycoplasma mastitis in a clinical stage is characterized by an altered milk consistency, a 
severe and sudden drop in milk production and a resistance to treatment (Jasper, 1982). 
Another typical trait of the infection is that multiple quarters can be affected, due to the 
capacity of the bacterium to spread hematogenously (Jasper, 1982;, Pfützner and Sachse, 
1996; Rosengarten and Citti, 1999). Milk consistency can vary from watery to purulent, 
though a watery milk with a fibrinous sandy sediment is very typical for the infection 
(Jasper, 1982; Pfützner and Sachse, 1996). Incubation generally takes 2-10 days before 
mastitis is seen, during which shedding can already occur (Pfützner and Sachse, 1996; Al-
Farha et al., 2017). Affected cattle can remain clinically normal as well, even when the 
udder has already been severely compromised, and can act as subclinical carriers of the 
bacterium for a longer period, shedding M. bovis intermittently (González and Wilson, 
2003; Nicholas et al., 2016; Timonen et al., 2017). Subclinical carriers will often have an 
increased somatic cell count (SCC), a lower daily milk production (on average 3 l less) and 
a lower fat and urea content in milk (Al-Farha et al., 2017; Timonen et al., 2017). Shedding 
can persist throughout the lactation and even carry over into the next lactation, although 
some cows were reported to have eliminated the infection themselves (González and 




Wilson, 2003). Cases of dry cows being affected by M. bovis mastitis without preexisting 
infection in a previous lactation have been reported (Pfützner and Sachse, 1996). 
Interestingly, M. bovis has been reported to cause mastitis in prepubertal heifers as well, 
resulting in nodules in the udder and one or multiple dry quarters in the first lactation 
(Fox et al., 2008). In these instances, hematogenous spread out of other sites of infection 
was assumed (Fox et al., 2008).  
Histologically, acute M. bovis mastitis is characterized by degeneration of the epithelium 
of the alveoli combined with a leukocyte exudation (González and Wilson, 2003). 
Chronically, plasma cells will start to infiltrate the interalveolar space, combined with a 
progressive fibroplasia of the milk ducts and atrophy of the udder alveoli or even 
abscessation (González and Wilson, 2003). Antimicrobial therapy of Mycoplasma mastitis 
is often very disappointing, even when a systemic approach is combined with local 
treatment. As such, together with the inconsistent shedding and the variable duration of 
clinical symptoms, M. bovis mastitis is considered untreatable by a multitude of sources 
and affected cattle should be considered lifelong infected (Pfützner and Sachse, 1996; 
Nicholas et al., 2016; Timonen et al., 2017). As a consequence, most control programs 
recommend the culling of affected animals (Pfützner and Sachse, 1996; Nicholas et al., 
2016). However, some researchers have reported success in treating M. bovis mastitis 
with intensive antimicrobial therapy (Byrne et al., 1998). 
Even though M. bovis is often found together with other mastitis pathogens, no significant 
effect of M. bovis mastitis in coinfection with other bacteria was found in a study by 
Timonen et al. (2017). Al-Farha et al. (2017) did not see a difference in mastitic milk 
composition of M. bovis coinfection compared to conventional mastitis pathogens either. 
3.2. PNEUMONIA 
Respiratory disease due to M. bovis can develop in cattle of any life stage, even affecting 
neonatal calves as young as 5 days postpartum (Stipkovits et al., 2000). The disease is 
characterized by fever, anorexia, dyspnea, depression, coughing and rhinorrhea 
(Stipkovits et al., 2000). Most commonly, pneumonia due to M. bovis is seen in young 
calves between 2 to 6 weeks of age (Stipkovits et al., 2000; Maunsell and Donovan, 2009). 
Coinfection with Bovine Viral Diarrhea Virus can worsen the clinical signs (Shahriar et al., 
2002; Gagea et al., 2006). As M. bovis can downregulate the immunological reaction, it can 
also act as a predilecting factor to facilitate infection with or worsen the symptoms of 




other respiratory pathogens such as Mannheimia haemolytica, Pasteurella multocida, 
Histophilus somni, Bovine Respiratory Syncytial Virus and others, which is why M. bovis is 
considered a part of the bovine respiratory disease complex (BRD) (Caswell and 
Archambault, 2008). M. bovis pneumonia is associated with four main kinds of lesion 
patterns: suppurative bronchopneumonia without necrosis, caseonecrotic 
bronchopneumonia, bronchopneumonia with coagulation necrosis foci and chronic 












Figure 2: Purulent mastitis in a Belgian Blue  Figure 3: Caseonecrotic lesions and pneumonia of 
the lung (Source: Han Versnaeyen, DGZ) Figure 4: Fibrinous arthritis of the carpus due to M. 
bovis Figure 5: Calf with a typical head tilt due to M. bovis, combined with a failure to thrive  
compared to other calves of the same age group. 
2 3 
4 5 




In a caseonecrotic bronchopneumonia, M. bovis can persist for a long time extracellularly 
in the necrotic foci, evading the immunity of the infected animal even when being 
surrounded by neutrophils and macrophages (Kleinschmidt et al., 2013). Lesions are 
often focused on the cranial and middle lung lobes, but can affect the rest of the lung too 
in severe cases (Caswell and Archambault, 2008). Caseonecrotic lesions composed of 
necrotic nodules (mm to cm in diameter) surrounded with consolidation of the lung on 
autopsy are seen as an indicator for the presence of M. bovis (Shahriar et al., 2002; Gagea 
et al., 2006). M. bovis pneumonia often turns chronic, with M. bovis persisting in the 
necrotic lesions as well.  
3.3. ARTHRITIS 
Although M. bovis associated arthritis is more commonly seen in calves, this disease form 
has been reported in adult cattle as well (Wilson et al., 2007; Maunsell and Donovan, 
2009). Affected animals become acutely lame with swelling of joints and tendon sheaths 
and high fever (Stalheim and Page, 1975; Adegboye et al., 1996; Hewicker-Trautwein et 
al., 2002). Large rotator joints, such as for example shoulder, elbow, and knee are 
commonly affected (Maunsell and Donovan, 2009). When opened, a pyogranulomatous to 
serofibrinous synovitis, bursitis and/or tenosynovitis can be observed (Stipkovits et al., 
1993; Adegboye et al., 1996) (Figure 4). The amount of joint fluid increases, and might be 
turbid and contain fibrin (Ryan et al., 1983). Cartilage will start eroding, and gets replaced 
by fibrous connective tissue (Ryan et al., 1983). In experimental conditions, ulceration of 
the distal planum of the knees was seen, with secondary rupture of the synovial sac 
(Stalheim and Page, 1975). The most commonly accepted pathway of infection of the joint 
is through hematogenous spread out of a primary site, usually the lungs (Thomas et al., 
1986; Rosengarten and Citti, 1999). As such, animals affected with M. bovis induced 
arthritis will usually have lesions in other organs such as lungs or udder as well (Stalheim 
and Page, 1975; Adegboye et al., 1996; Gagea et al., 2006). Response to therapy is poor, 
affected animals are usually culled though arthrodesis can be an option if only one joint is 
affected (Van Huffel et al., 1989; Maunsell and Donovan, 2009). Persistence of M. bovis in 
the joint for up to 28 days has been described (Stalheim and Page, 1975).  




Figure 6 and 7: Contrast CT images showing a marked increase in contrast in the brain 
 at the site of an otitis interna (green arrows). (Source: Linde Gille, 2014 master’s thesis) 
3.4. OTITIS 
Mycoplasma bovis is a cause of otitis media in such a high number of cases, that the disease 
has been termed a “Mycoplasma bovis associated disease”, just like pneumonia and 
arthritis, and can act as an indicator for M. bovis presence on a farm (Maunsell and 
Donovan, 2009). Other potential bacterial causes of both pneumonia and otitis are H. 
somni, P. multocida and M. haemolytica (Duarte and Hamdan, 2004). Calves affected with 
M. bovis otitis are generally lifeless, lay down more often compared to their non affected 
counterparts and usually portray a uni- or bilateral ear droop with a head tilt, fever and 
epiphora (Walz et al., 1997; Francoz et al., 2004; Foster et al., 2009) (Figure 5). Otitis 
media often causes chronic weightloss and wasting, and can result in otitis interna and 
meningitis with abscessation of the temporal bone if it goes untreated (Walz et al., 1997; 
Maeda et al., 2003)(Figure 6&7). On pathology, affected tympanic bullae are filled with a 
fibrinosupporative to caseous exudate (Walz et al., 1997). Cases are usually chronic and 
respond poorly to antimicrobial use (Maunsell and Donovan, 2009). The disease has been 
linked to the feeding of M. bovis infected waste milk or feed with subsequent colonisation 
of the tonsillae and eustachian tube, whereas transtracheal inoculation of M. bovis did not 
manage to induce otitis experimentally (Maeda et al., 2003; Foster et al., 2009; Maunsell 








3.5. REPRODUCTIVE DISEASES 
Even though reproductive diseases caused by M. bovis were described as early as 1964, 
their importance in the M. bovis disease complex was seemingly disregarded later on 
(Doig, 1981; Maunsell et al., 2011). In recent years, the attention to these diseases  is  
rising again, probably at least partially due to the unknown pathway of introduction of M. 
bovis in New Zealand and recent introductions via artificial insemination (AI) into M. bovis 
negative closed herds in Finland (Ministry for Primary Industries, 2017; Haapala et al., 
2018).  
Inoculation of M. bovis into the uterus of mature heifers leads to salpingitis, endometritis 
and salpingoperitonitis with ovarian adhesions (Hirth et al., 1966; Doig, 1981). 
Microscopically, chronic inflammation is present after inoculation of M. bovis in the 
uterine tract (Fabricant, 1973). Insemination with live M. bovis contaminated semen will 
lead to an increase in the number of inseminations required before conception (Hirth et 
al., 1966). In vitro as well, M. bovis infected semen will cause a lower number of developing 
embryos compared to control groups (Bielanski et al., 2000).  
Even though the importance of M. bovis in the whole of bovine abortion cases is unknown, 
experimental inoculation of M. bovis into fetal membranes or intravenously can lead to 
abortion and M. bovis DNA has been detected in spontaneous abortion cases too (Stalheim 
and Proctor, 1976; Bocklisch et al., 1986; Kirkbride, 1987; Houlihan et al., 2007; Hermeyer 
et al., 2012).  
In bulls, M. bovis can also be isolated from the genital tract, where it can induce seminal 
vesiculitis (Jasper et al., 1974a; LaFaunce and McEntee, 1982). Vesiculitis could not be 
reproduced when M. bovis was administered intravenously, only after local inoculation by 
LaFaunce and McEntee (1982). Even though natural cases of seminovesiculitis have been 
described, after preputial inoculation of M. bovis, Kreusel et al. (1989) did not manage to 
induce clinical disease except for mild local inflammation in some animals, indicating a 
possible strain dependence or interaction with other pathogens (Rosengarten and Citti, 
1999). There seem to be differences in the distribution of M. bovis’ presence in the seminal 
tract as well, as in Western Europe, Australia and America the bacterium was only seldom 
present in targeted searches, whereas in Hungary at one point 37% of all semen samples 
were positive for M. bovis (Kirkbride, 1987; Petit et al., 2008).   
3.6. OTHER PRESENTATIONS 






In addition to the above mentioned M. bovis disease forms, several other presentations 
have been described to date. Since the bacterium can spread hematogenously, it is not 
rare to isolate it out of different organs. M. bovis can often be isolated out of conjunctival 
swabs in cattle affected with other symptoms of mycoplasmosis. When 
keratoconjunctivitis coincides with respiratory problems in a herd, M. bovis testing should 
be advised (Levisohn et al., 2004; Alberti et al., 2006). Kinde et al. (1993) described an 
outbreak of M. bovis infected subcutaneous decubital abscesses, where the area around 
the joints and brisket were affected without involvement of the joints. M. bovis meningitis 
can occur as a consequence of otitis interna, but has been described without the presence 
of an otitis interna as well (Stipkovits et al., 1993; Gosselin et al., 2012). In some cases, 
polyserositis and pericarditis was also present (Stipkovits et al., 1993). 
Table 2: Sampling sites in live animals for different M. bovis presentations 
Disease Suggested sample Test Source 




DNS, conjunctival swab 
(might be more effective 
compared to DNS) 
Culture, PCR 
Sachse et al., 2010, 
Soehnlen et al., 2012 
Arthritis Synovial fluid Culture, PCR Maunsell et al, 2011 
Otitis Tonsil swabs, (DNS) Culture, PCR Maunsell et al, 2012 
Keratoconjunctivitis Conjunctival swab Culture, PCR Maunsell et al, 2011 
Screening for 
carriers 
DNS, vaginal swab, 
conjunctival swab, 
serum, milk, (BAL), 
semen 
Culture, PCR, Ab ELISA 
Soehnlen et al., 2012, 
Parker et al., 2017b, 
Hazelton et al., 2018 
PCR: Polymerase Chain Reaction, Ab ELISA: Antibody Enzyme-Linked Immunosorbent Assay; 
DNS: Deep Nasopharyngeal Swab 





4.1. ANIMAL LEVEL 
The appearance of typical clinical symptoms like otitis, arthritis or therapy resistant 
mastitis in multiple animals is usually the first sign of M. bovis introduction into a herd 
(Pfützner and Sachse, 1996). Early diagnosis at animal level is necessary, also when trying 
to remove carriers from a herd (Pfützner and Sachse, 1996). Sampling of the affected 
organ or one of the known carrying sites of M. bovis will give the highest sensitivity for 
detection. However, since M. bovis can be shed intermittently, a negative sample is no 
conclusive indicator that the tested animal is not a carrier of M. bovis (González and 
Wilson, 2003). When trying to diagnose M. bovis pneumonia, 94% of all calves with 
pneumonic lesions tested positive on nasal swabs as well, providing a more easily 
accessible sample method (Soehnlen et al., 2012). Next to the live bacterium or M. bovis 
DNA, antibodies can be detected in various substrates as well. Important to note is that 
very little shedding at other body sites could be shown in cows having had a clinical M. 
bovis mastitis recently (Hazelton et al., 2018). 
4.1.1 CULTURE 
The routine diagnosis of M. bovis associated disease in an animal is often still made by 
culturing samples taken from an affected organ or a common carrying site (Parker et al., 
2018). As a consequence of the hematologic spread of the bacterium, the same M. bovis 
strain can be present at multiple organ sites (Pfützner and Sachse, 1996; Biddle et al., 
2005). Due to their minimalistic nature, mycoplasmas cannot synthesize essential amino 
acids and need highly enriched growth media with a pH of 7.3-7.8 in order to grow 
successfully (Razin et al.,1998).  
Culture is preferably done on specific pleuropneumonia-like (PPLO) agars or in liquid 
growth media with added selective antimicrobials, at 37°C with an increased moisture 
level and the addition of 5-10% CO2 (Bushnell, 1984; Pfützner and Sachse, 1996; Fox et 
al., 2003). Culture has a high sensitivity and specificity (up to 10-102 CFU/ml when liquid 
samples are inoculated), but takes time. Due to the relatively slow growth of M. bovis, 
definite interpretation of the plates as negative can only be done after 7-10 days 
(Bushnell, 1984; Pfützner and Sachse, 1996). However, plates should be checked daily by 
use of a (stereo-) microscope for early growth or contamination. M. bovis colonies have a 
typical fried egg shape, formed because the central zone of the colony grows denser and 




into the medium, whereas the surrounding zone only grows on the surface (González and 
Wilson, 2003). Culture can lack specificity to distinguish between commensal and 
pathogenic Mycoplasma species, as multiple species can grow on Mycoplasma media (Fox 
et al., 2005). Several agars are available which will give a characteristic reaction in the 
presence of M. bovis, such as agars with added Tween 80 (Devriese and Haesebrouck, 
1991) and M. bovis specific diagnostic agars which will give a color change when M. bovis 
is present (Mycoplasma Experience Ltd, Surrey, UK). 
For milk samples, 10µL of milk is usually inoculated to detect Mycoplasma. As such, the 
detection limit of this technique is 100 CFU/mL, which can be improved by centrifuging 
the sample before inoculation (Parker et al., 2018). While culture is an easily accessible 
technique, there are a lot of caveats. Due to the slow growing nature of M. bovis, it will 
often get overgrown by contaminants before diagnosis is made. As such, sampling and 
subsequent storage need to be performed as sanitary as possible, and samples should be 
stored cooled or frozen if culture cannot happen immediately (Parker et al., 2018). 
However, freezing milk samples containing M. bovis will cause at least a 1 log reduction, 
possibly resulting in a false negative culture afterwards, especially when the samples have 
a relatively low number of M. bovis such as in the case of bulk tank milk (BTM) samples 
(Boonyayatra et al., 2010). Animals need to be shedding to test positive, which means a 
single culture can be insufficient to identify carriers (Biddle et al., 2003; Hazelton et al., 
2018). When animals have been treated with antimicrobials, M. bovis might not grow 
anymore in vitro, possibly resulting in false negative results (Caswell and Archambault, 
2008).  
4.1.2 ANTIBODY ELISA 
Antibodies against M. bovis can be detected in individual serum and milk samples 1-2 
weeks after the initial M. bovis exposure by use of an enzyme-linked immunosorbent assay 
(ELISA) (Nicholas et al., 2002). This technique can be used on BTM samples as well 
(Boothby et al., 1987; Nielsen et al., 2015). The primary advantage of this technique 
compared to culture and PCR is that bacteria do not need to be present at the time of 
sampling for the animal to test positive (Petersen et al., 2018a). Antibodies were shown 
to stay present for at least 6 months after the initial exposure in a vaccination experiment, 
although recent work has shown a rapid decline of antibodies in milk after initial disease 
onset, with a mean drop below the cutoff ODC% at 65 days past infection and the lower 




95% CI only being above the ODC% cutoff for 10 days (between 7 and 17 days after 
disease onset) when using a BIOX K302 ELISA (BioX)(Nicholas et al., 2002; Petersen et al., 
2018a). Furthermore, not all affected cattle will develop high antibody titers, possibly 
decreasing the sensitivity of these tests (Maunsell et al., 2011). BIOX ELISA results were 
shown to have no correspondence with PCR and culture results except for what can be 
explained by chance, possibly resulting in an increased detection rate when using a 
combination of tests together (Parker et al., 2017a; Parker et al., 2017b).  
Although specific ELISA kits on milk are often used to screen for shedders, the sensitivity 
of these tests drops rapidly when only systemic infection is present without udder 
involvement (Petersen et al., 2018a). Antibodies also stay present longer in infected 
quarters compared to non-infected quarters in the same animal, an indication that the 
immune response is mainly a localized immunity (Byrne et al., 2000; Petersen et al., 
2018a). In general, due to the large individual variation in antibody production, the 
reliability of ELISA tests is deemed questionable, generally unreliable for individual 
diagnosis and probably leading to an underdiagnosis of shedders (Pfützner and Sachse, 
1996; Petersen et al., 2018a). As such, ELISA use for individual diagnosis has been 
discouraged in recent years, though the test still has merit in herd level screening 
protocols. A recent Australian article has shown that an indirect IgG ELISA test (MilA 
ELISA) developed by Wawegama at al. (2014) did have better sensitivity when compared 
to the BIOX K302 test on the same sample set of serum of young calves (Petersen et al, 
2018b). Further research is necessary to evaluate the usability of this new test.  
4.1.3 ANTIGEN ELISA AND IMMUNOBLOT 
Before the rise of ready to use PCR assays, antigen ELISA and immunoblot assays directly 
detecting M. bovis in clinical samples were proposed as a faster alternative compared to 
culture, reducing the time till diagnosis from a week to days or even only hours (Infante 
Martinez et al., 1990; Heller et al., 1993, Sachse et al., 1993). Detection limit of the 
immunoblot when using monoclonal antibodies generally laid around 5 x 103 CFU/mL, 
and analysis took 2-3 hours to complete (Infante et al., 2002). An immunoblot detecting 
M. bovis in semen was also developed, boasting the same 5 x 103 CFU/mL detection limit, 
with a sensitivity of 83.3% and a specificity of 100% (Flores-Gutierrez et al., 2004). A 
combination technique using the antigen capture technique of antigen ELISA to then 




perform PCR on these samples, increasing the sensitivity of said PCR to 2-20 CFU/mL has 
been described as well (Hotzel et al., 1999). 
4.1.4 POLYMERASE CHAIN REACTION (PCR) 
When PCR was initially developed, it was usually applied for the identification of 
Mycoplasma species out of already cultured samples. Later on, development of (real time) 
PCR techniques that could be performed on clinical samples allowed to directly detect M. 
bovis DNA, without the need of culturing beforehand (Cremonesi et al., 2007; Parker et al., 
2017b). Real time PCR techniques have reduced the time till a diagnosis can be reached, 
thus leading to a faster response time on affected farms, seemingly without a reduction of 
the sensitivity. Detection of 10 CFU/ml in milk is possible, although this detection limit 
depends on the technique and sample used (Cremonesi et al., 2007). A PCR method 
optimized by Behera et al. (2018), targeting the uvrC gene was called 103 times more 
sensitive compared to normal PCR (Rossetti et al., 2010; Behera et al., 2018). However, 
recent research has also shown that the agreement between Mycoplasma culture and 
multiplex probe PCR identification on semen or swabs can be a lot lower at only 75% 
agreement (Parker et al., 2017b). One other downside of PCR is that, as with culture, M. 
bovis needs to be present in the sample in order to detect it, and thus intermittent 
shedders might escape detection. However, in contrast with culture, M. bovis does not 
need to be alive for PCR based detection (Caswell and Archambault, 2008). PCR is a more 
expensive technique compared to culture, which has resulted in sample pooling in 
practice (Murai et al., 2014). 
4.2. DIAGNOSIS AT HERD LEVEL 
Historically mainly culture of animal samples or bulk tank milk was available to assess 
the prevalence of M. bovis in a herd (Sachse et al., 1993). However, as described above, 
this requires a specialized medium and time. Next to this, the sensitivity of culture on bulk 
tank milk (BTM) is affected by the intermittent excretion of M. bovis in milk, the dilution 
of the number of bacteria in the whole tank and the fact that the milk of clinical M. bovis 
shedders is usually withheld from the tank (González and Wilson, 2003; Fox et al., 2005). 
Sensitivity of a single BTM culture for the detection of M. bovis infected herds was found 
to be between 33-59% when at least one cow in the herd was positive for Mycoplasma, 
with the concentration of bacteria not being predictive of the percentage of shedders 
(González and Wilson, 2002; González and Wilson, 2003). Culturing at least 3 BTM 




samples 3-4 days apart will result in a 70% probability of the milked cows being 
uninfected if all samples test negative (González and Wilson, 2002; González and Wilson, 
2003). In herds affected by M. bovis pneumonia, 64-90.4% of all nasal swabs tested 
positive for the bacterium (Soehnlen et al., 2012).  
The development of commercial antibody ELISA and PCR tests have facilitated M. bovis 
screening in animals, as they are less time-consuming compared to culture, and both 
techniques have been validated for use on BTM and composite milk samples as well (Cai 
et al., 2005; Nielsen et al., 2015; Petersen et al., 2016; Parker et al., 2017a). The sensitivity 
and specificity of the most commonly used commercially available ELISA on BTM is 
estimated to be 60.4% (95% CI: 37.5-96.2) and 97.3% (95% CI: 94-99.8) respectively 
when using the suggested ODC% of 37% (Bio-X BIO K 302, Bio-X Diagnostics, Rochefort, 
Belgium) (Nielsen et al., 2015). The specificity can be raised (with a decline in sensitivity) 
by using an ODC% of 50%, as suggested by Nielsen et al. (2015) 
However, before the BTM sample will test positive by use of AbELISA, 30% of the lactating 
animals in a herd need to produce antibodies against M. bovis (Petersen et al., 2016). After 
a clinical mastitis outbreak, antibodies can generally stay detectable in BTM for up to 8 
months, but antibody positive young stock does not influence the BTM optical density 
measurement, making it hard to detect a youngstock outbreak by use of this method 
(Petersen et al., 2016; Parker et al., 2017a). Because the BTM antibody level fluctuates, it 
is possible that the antibody levels in BTM drop faster than this as well (Petersen et al., 
2016). PCR has a higher sensitivity, but relies on the active excretion of M. bovis (Sachse 
et al., 2010). BTM was the only sample type where PCR could detect more M. bovis positive 
samples compared to culture (Parker et al., 2017b). As M. bovis is shed intermittently, and 
the milk of mastitic cows is supposed to be withheld from the BTM, this could however 
lead to an underestimation of the M. bovis herd prevalence when relying solely on a single 
PCR analysis (Petersen et al., 2016). Interestingly, PCR and Ab ELISA results showed no 
agreement, except what could be explained by chance in a study by Parker et al. (2017a). 
This could mean that using both tests in parallel could raise the sensitivity of correctly 
identifying positive herds.   





Epidemiology studies the distribution and determinants of disease and the application of 
these factors in the control of said diseases. Especially in the case of M. bovis, 
epidemiological studies are of utmost importance since vaccination is currently 
unavailable and prognosis is poor. As such, in this section, we delve into the importance 
of M. bovis in Europe, the transmission of M. bovis between animals, the currently 
identified risk factors at herd level and the relevance of molecular epidemiology of M. 












Figure 8: Possible pathways of M. bovis transmission. Dashed lines signify between herd 
transmission, full lines within herd transmission. Orange lines have been suggested but 
need further research. 
5.1. M. BOVIS IN EUROPE 
After the identification of M. bovis in California in 1962, testing of bovine samples 
gradually started and the geographical spread of M. bovis was mapped (Hale et al., 1962; 
Reeve-Johnson, 1999). M. bovis was isolated throughout North America (1962), Israel 
(1964), Canada (1976), Europe (probably after introduction from America) (1971-1981) 
and Japan (1977) (ter Laak et al., 1992; Ball, 1999). In early years the prevalence of the 
pathogen seemed to be quite low and concentrated in veal and beef herds (ter Laak et al., 
1992; Reeve-Johnson, 1999). In 1992, the first report was made on the rising prevalence 




of M. bovis in Europe by ter Laak et al. (1992), who saw an increased incidence of 
pneumonia, mastitis and arthritis in the Netherlands in the years before this report. In the 
last decade, M. bovis has become a common finding in pneumonia cases in Western 
Europe. In Italy, 76% of beef cattle and 100% of veal calves presenting with pneumonia 
at slaughter were found to be carriers of antibodies against M. bovis (Radaelli et al., 2008). 
Similarly, veal operations in France and Belgium also tested around 100% positive for M. 
bovis antibodies (Arcangioli et al., 2008, Pardon et al., 2011). 
In Northern Ireland, M. bovis got established in 1993, probably imported from mainland 
Europe after a relaxation of border regulations within the EU (Brice et al., 2000). Between 
1993-1998, 15% of all pneumonia cases in Northern Ireland tested positive for M. bovis, 
reflecting the findings in the Republic of Ireland as well, where between 1995-1998, 18% 
of all pneumonic lungs tested positive (Brice et al., 2000; Byrne et al. 2001). M. bovis 
associated mastitis cases were barely seen during this time. Also in the next follow up 
period, between 1999-2005, there were hardly any cases of M. bovis mastitis found, 
though the prevalence of M. bovis in pneumonia rose to 20% (Blackburn et al., 2007). In 
Hungary, M. bovis was isolated early on, in 1977, and in 2004 11.3% of all animals were 
seropositive (Fodor et al., 2017). A recent serological study performed in 2017 on 86 
herds throughout Hungary unveiled that all Hungarian herds tested had at least 2/10 
animals serologically positive, with 88.38% of all herds having more than 50% 
seropositive animals (Fodor et al., 2017). 
Several European countries managed to steer free of the disease until recently (Härtel et 
al., 2004; Gulliksen et al., 2009; Spergser et al., 2013). Austria had, for example, until 2007 
only one confirmed case of M. bovis mastitis (Spergser et al., 2013). In 2007, M. bovis was 
found in a large herd, causing devastating disease of cattle and even pigs housed in the 
same farm (Spergser et al., 2013). The following years the same strain spread to further 
Alpine areas, causing more animal losses (Spergser et al., 2013). Finland and Sweden 
stayed free of the disease for a long time as well, but were found to be positive in 2012 
and 2011 respectively, albeit at very low prevalence (SVA, 2018; Haapala et al., 2018). A 
full overview of all known M. bovis prevalence levels at herd level in Europe, determined 
by either ELISA, PCR or culture is depicted in figure 9. In Belgium, two studies determined 
the herd level prevalence of M. bovis, finding 1.5% of all dairy herds positive on culture of 
BTM in 2009, and 11% of the calves sourced from diverse dairy herds serologically 
positive (Passchyn et al., 2012; Pardon et al., 2015). Early on, mainly the respiratory 




component of M. bovis was seen as a problem, especially in veal herds, but more recently 
the number of M. bovis related mastitis cases has risen enormously (Passchyn et al., 2012). 
PCR analysis on 577 (mainly BAL and DNS) samples collected between 1 December 2016 
and 31 October 2018 in Belgian herds suffering from a respiratory disease outbreak 
resulted in 28.4% of the samples having M. bovis DNA presence confirmed (DGZ, 2018). 
 
Figure 9: Herd-level M. bovis prevalence in Europe determined by use of different techniques 
Prevalence data on this map were gathered by a thorough search of various e-libraries, and were 
published in literature or online between 2002 and 2018. The colors correspond with the type of 
test used: green stands for PCR on bulk tank milk, red for serological ELISA, blue for culture of 
bulk tank milk, and pink for ELISA on bulk tank milk. Black stands for a prevalence number 
mentioned without distinction of the method to obtain said number. A: Pinho et al. (2013); B: Le 
Grand et al. (2002); C: Arcangioli et al. (2011); D: Passchyn et al. (2012); E: Pardon et al. (2012); 
F: Hogenkamp (2017); G: Nielsen et al. (2015); H: Arede et al. (2016); I: Gulliksen et al. (2009); J: 
SVA (2018); K: Haapala et al. (2015); L: Timonen et al. (2017); M: Bednarek et al. (2012); N: 
Surýnek et al. (2016); O: Fodor et al. (2017); P: Burnens et al. (1999) ; Q: Filioussis et al. (2007)  





Purchase of a (sub)clinical carrier animal M. bovis is generally believed to be the major 
route of introduction into a herd (Maunsell et al., 2011). Once inside, this carrier will cause 
infection of other animals, immediately or once shedding is resumed, after which the 
pathogen will spread through the infected farm (Pfützner and Sachse, 1996). Stress, as 
induced by transport and handling, can increase shedding in nasal secretions, possibly 
worsening the initial spread from the introduced carrier animal (Caswell and 
Archambault, 2008). Stress factors (such as transport, overcrowding, moldy feed and 
disease) in either adult or calf groups were determined to be a herd-level risk factor for 
M. bovis as well (Aebi et al., 2015). Between adult cattle, the most commonly accepted 
pathways of M. bovis transmission are direct contact, contact with aerosols and 
transmission during the milking process (Jasper et al., 1974b; González and Wilson, 2003; 
Maunsell et al., 2011). Calves will usually get infected by consumption of milk 
contaminated with M. bovis, or via direct contact with other carriers (Pfützner and Sachse, 
1996; Maunsell and Donovan, 2009; Maunsell et al., 2012). 
Several other pathways of transmission have been suggested in the past, such as vertical 
transmission from the mother to the unborn calf and transmission via colostrum, vaginal 
secretions, fomites, semen, aerogenous spread and transmission out of the environment. 
Identification of all possible infection routes and their relative importance is necessary 
for the design of effective biosecurity protocols and M. bovis management directives. In 
the next paragraphs an overview of current evidence of these suggested routes of 
transmission is provided.  
5.2.1. VERTICAL TRANSMISSION, VAGINAL SECRETIONS, SEMEN AND EMBRYOS 
Vertical transmission was reported as a possible route of transmission after isolation of 
M. bovis out of uteri, aborted foeti and neonati (Stalheim and Proctor, 1976; Pfützner and 
Sachse, 1996). When abortion was induced by inoculation of M. bovis into the amniotic 
fluid, the bacterium could be isolated out of the foetus (Stalheim and Proctor, 1976; 
Bocklisch et al., 1986). M. bovis was shown to be present in the lungs of a preterm calf that 
died of respiratory problems a few hours after birth as well (Hermeyer et al., 2012). 
However, the prevalence and importance of vertical transmission remains a question. 
Since M. bovis can be found in vaginal swabs and aborted feti, the assumption can be made 
that M. bovis induced abortions or premature births could be a source of infection for 




other cows in the herd. Thus far however, to the author’s knowledge, no research has been 
done on this topic. In the tracing of M. bovis’ point of entrance in New Zealand, the trade 
of embryos to be used in embryotransfer was also taken into consideration (Ministry for 
Primary Industries, 2017). Although M. bovis has been isolated from embryos in vitro 
before and commonly used antimicrobials were shown to be ineffective in eliminating the 
bacterium, the potential of transmission through embryo transplantation remains 
currently unknown (Bielanski et al., 1989; Bielanski et al., 2000). 
Semen can be a carrier of M. bovis, and when artificial insemination (AI) semen is stored 
in liquid nitrogen, M. bovis can stay infectious for years (Jasper et al., 1974a, b; Pfützner, 
1984). Since the usual combination of antimicrobials (gentamycin, tylosin, lincomycin and 
spectinomycin) added to AI semen was shown to be ineffective for M. bovis, the 
transmission from this semen to inseminated cattle is in theory possible (Pfützner and 
Sachse, 1996; Visser et al., 1999), and was shown to be practically possible after outbreaks 
in closed dairy herds in 2016 in Finland (Haapala et al., 2018). 
5.2.2. ENVIRONMENT 
M. bovis has the capacity to stay present on a variety of substrates, thanks to biofilm 
formation (McAuliffe et al., 2006). Among the substrates where M. bovis was isolated from, 
there are a lot of bedding materials, such as straw, manure and recycled bedding sand, 
which lead to the hypothesis that the environment could be factor in the transmission of 
M. bovis between animals or even production cycles (Pfützner, 1984; Wilson et al., 2011; 
Piccinini et al., 2015). A complete list of known substrates and their survival time can be 
found in table 3. 
There is however no definite proof that M. bovis can transmit to naïve animals from these 
bedding materials. In fact, Wilson et al. (2011) could prove with 97-99% certainty that 
recycled sand bedding was not a source of transmission in an experimental setting using 
a top dressing layer of infected sand in calf pens. Piccinini et al. (2015) have suggested 
that environment was the source of an infection with M. bovis in a veal herd, due to M. 
bovis isolates of calves and environment being “the same molecular (=strain) type”. 
However, this might be a misinterpretation of the data, as M. bovis has been shown to 
spread clonally when introduced into veal herds, with one strain getting the upper hand, 
which could mean that the environment got infected by the calves, and not vice versa 
(Soehnlen et al., 2012; Timsit et al., 2012). The survival of M. bovis in the environment was 




thought to have played a part in the transmission on a farm in cases of mastitis outbreaks 
described by Bray et al., where cooling ponds (used in summer by milking cows to avoid 
overheating) were found to be infected with the bacterium and cattle got mastitis after 
bathing in the infected ponds (Bray et al., 1997; Bray et al., 2001). In any case, the 
concentration of M. bovis found in for example bedding sand (103-106 CFU/g) is a lot 
higher than the minimum infective dose necessary to cause mastitis under experimental 
conditions (as low as 70 CFU/g) (Justice-Allen et al., 2010). 
Table 3: Survival of M. bovis on various materials present in a barn environment 
Tested material 
M. bovis presence 
confirmed in barn 
Temperature 
Survival time at given 
temperature 
Source 
Cotton no 20°C 5 days Pfützner, 1984 
Dirt calving pen yes ND ND Bray et al., 1997 
Manure yes 23-28°C 
236 days in dark /  
145 in light 
González and Wilson, 
2003, Justice-Allen et 
al., 2010 
Metal cages and 
mangers 
yes ND 2 days 
Pfützner,1984,  
Piccinini et al., 2015 
Milk yes 4°C / 20°C 54 days / 10 days Pfützner, 1984 
Paper ND 
4°C / 30°C / 
37°C 
126 days / 28 days / 
14 days 
Nagatomo et al., 2001 
Sand yes 15-20°C 8 months 
Justice-Allen et al., 
2010 
Sponges ND 20°C 9 days Pfützner, 1984 
Straw yes 20°C 10 days 
Pfützner, 1984, 
Justice-Allen et al., 
2010 
Tap water no 20°C 8 days Pfützner, 1984 
Water of a 
cooling pond 
yes ND ND 
Bray et al., 1997, Bray 
et al., 2001 
Well water no ND 18-20 days Pfützner, 1984 
Wood no 20°C / 23-28 °C 17 days / <1 day 
Pfützner, 1984, 
González and Wilson, 
2003 
ND= not determined 
5.2.3. AIRBORNE SPREAD 




One study by Jasper et al. (1974a), who laid agars open in a stable and collected them 
afterwards, has described the isolation of M. bovis out of stable air. However, a more 
specialized study by Soehnlen et al. (2012) using air samplers failed to isolate M. bovis out 
of stable air. Spread in close quarters such as (overstocked) barns could be a risk, 
especially when housing different ages together, as inhalation of aerosolized M. bovis was 
shown to cause clinical disease (Maunsell et al., 2011; Kanci et al., 2017). Spread by air 
over longer distances as described for Mycoplasma hyopneumoniae in pigs has however 
probably no or very little importance for M. bovis spread (Nicholas et al., 2002; Otake et 
al., 2010; Kanci et al., 2017). 
5.2.4. MILKING EQUIPMENT 
Mycoplasma mastitis can easily be transmitted from one udder to the next through 
contaminated milking equipment, reuse of towels or dirty hands or gloves as well (Jasper 
et al., 1974b; González and Wilson, 2003). Since only a few M. bovis CFU are enough to 
induce mastitis when introduced via the teat canal, hygiene during milking time and post 
milking teat asepsis are of utmost importance to prevent the spread of disease (Jasper, 
1982; González and Wilson, 2003). Contaminated udder treatments (either reuse of 
antimicrobial applicators or contamination through improper storage or handling) and 
unhygienic teat disinfection were shown to be causes of M. bovis infection in the past 
(González et al., 1992; González and Wilson, 2003).  
5.2.5. VISITORS AND FOMITES 
When the first documented outbreak of M. bovis mastitis took place in 1962-1963, M. bovis 
was suspected to have spread between farms due to the visiting veterinarian, as it could 
be cultured from metal syringes and treatment materials (González et al., 1992). 
As M. bovis can be present in manure and bedding materials, all herd visitors, especially 
those visiting multiple farms such as milk truck drivers, merchants and veterinarians and 
all equipment shared between farms should be seen as an infection risk for the herd 
(González et al., 1992). 
5.2.6. COLOSTRUM 
Colostrum was suggested as a source of M. bovis infection for calves, but no research was 
ever published providing definite proof to this claim (Walz et al., 1997; Godden et al., 
2006; Foster et al., 2009).  




5.2.7. OTHER ANIMAL SPECIES 
Since M. bovis can, on occasion, infect other animal species and humans it is not unlikely 
that reinfection to cattle is possible (Madoff et al., 1979; Pfützner and Sachse, 1996; 
Spergser et al., 2013). However, no definite proof of this pathway is available either.   
5.3 HERD LEVEL RISK FACTORS FOR PRESENCE OF M. BOVIS  
5.3.1 PURCHASE 
Purchase is, without a doubt, the main risk factor when looking at M. bovis introduction at 
herd level (Jasper, 1981; González et al., 1992). This is no surprise, since M. bovis is often 
carried by non-clinical shedders, making it difficult to identify on sight (González and 
Wilson, 2003). Furthermore, any other kind of herd movement where animals of different 
herds are gathered, such as trade shows and livestock expositions, should be seen as a 
risk of transmission, and animals should be quarantined after returning to the herd 
(González and Wilson, 2003; Aebi et al., 2015). Interestingly, Aebi et al. (2015) who found 
that animal movement (trade and exposition) could raise the odds of having a M. bovis 
detectable presence by 8.3 on univariable analysis, also found purchase of replacements 
not to be a risk factor for M. bovis detection in already exposed herds, except as a source 
of stress (transport). This could however be a result of the study setup and the small 
statistical power, combined with the relatively low prevalence of M. bovis in the study area 
(Aebi et al., 2015). In herds already having M. bovis present, introduced cattle will also be 
at risk of acquiring M. bovis associated disease (Nicholas et al., 2016).  
5.3.2 HERD SIZE 
In the years after M. bovis’ first identification as a cause of mastitis in the USA, herds with 
a larger number of animals seemed to have a higher incidence of M. bovis related disease 
(Nicholas et al., 2016). In 1981, Thomas et al. found a significant correlation between herd 
size and culling percentage with M. bovis mastitis in Californian herds, but they were 
unable to make a distinction between cause and effect for culling, whether herds with M. 
bovis had a higher culling rate, or herds with a higher culling rate had more purchase, and 
thus more risk to having imported M. bovis into a herd. A correlation between larger herds 
and M. bovis detection in the herd was also seen by Uhaa et al., (1990), Fox et al. (2003), 
Pinho et al. (2013) and McCluskey et al. (2003). Herd size was however not observed as a 
risk factor in a study conducted by González et al. (1992) in the state of New York between 
1972 -1990.  





Seasonal variation in M. bovis outbreaks was seen in American herds, where Mycoplasma 
mastitis was more prone to be present from late fall till spring, with a peak around January 
(González et al., 1992). This seasonality was suggested to be caused by improper 
ventilation in barns during the winter months (Jasper, 1982). In a large retrospective 
study, there was a significant seasonal distribution in otitis cases as well, with the highest 
number of cases being present in spring, and the lowest in summer (Lamm et al., 2004). 
Interestingly, this seasonal variation was not seen in a large study in Great Britain that 
analysed a 10 year period of M. bovis associated disease (1995-2005) (Nicholas et al., 
2008).  
5.3.4 WITHIN HERD MANAGEMENT 
In a small scale Swiss study, a variety of milking process related risk factors were 
evaluated as possible risk factors for M. bovis positive PCR tests on composite milk 
samples or nasal swabs (Aebi et al., 2015). In the above study, after univariable analysis, 
high mean milk production of the herd, forestripping, additional stimulation before milk 
letdown and a certain milking machine brand were all determined to be potential risk 
factors for herd-level M. bovis presence (Aebi et al., 2015). High mean milk production 
was suggested to be a source of stress, possibly by causing cattle to be in a negative energy 
balance, whereas the increased handling of teats before milking could have been a source 
of pathogen transfer between animals (Aebi et al., 2015).  
The use of a sick pen to isolate animals out of the main herd instead of immediately culling 
M. bovis mastitis affected animals was shown to raise the odds of other cows in the pen 
getting infected, but the complete lack of a sick pen has also been identified as a risk factor 
(Punyapornwithaya et al., 2011; Fox, 2012). Cows returning from the sick pen to the main 
herd should be followed closely for signs of mastitis or mycoplasmosis, to avoid having 
too many shedders in the main herd (Nicholas et al., 2016). Herds with methods in place 
to identify problem cows (color markers, leg tags) were shown to have less risk of having 
detectable M. bovis in the BTM (Pinho et al., 2013). In veal herds, the mixing of age groups 
was shown to be a significant risk factor for seroconversion to M. bovis, with animals 
showing severely reduced weight gain during seroconversion and a severe increase in 
antimicrobial use (Tschopp et al., 2001).   
5.4 WITHIN HERD CIRCULATION 




Once M. bovis has entered a herd, transmission will happen between animals. However, 
the degree of transmission will vary in time. After the initial mastitis outbreak caused by 
a single strain in a previously non infected herd, Punyapornwithaya et al. (2010) found 
33.5% of all (mostly nonclinical) animals positive on one or more body sites with culture 
in the first three months after the outbreak. This decreased to 1.4-5.6% of the animals 
testing positive in the next year of sampling without any more incidences of M. bovis 
mastitis (Punyapornwithaya et al.,2010). In an Estonian cross-sectional study, 17.2% of 
all animals of a single herd (n=522) were found to be positive on PCR for M. bovis DNA on 
individual composite milk samples at a single time point (Timonen et al., 2017). In veal 
calf rearing facilities, nasal colonization by M. bovis was shown to happen quickly after the 
introduction of the calves into the herd, with 90% of all animals having had at least one 
nasal swab positive at 100-120d of age (Soehnlen et al., 2012). 
5.5 MOLECULAR EPIDEMIOLOGY 
Molecular epidemiology is becoming an invaluable tool to determine the origin of M. bovis 
strains and the route or source by which they entered a specific farm or region (Nicholas 
et al., 2016). By strain typing, one can also determine whether a strain is herd specific, 
whether different strains cause different types of disease, and even (through DNA 
sequencing) whether specific loci are predisposing for antimicrobial resistance or strain 
dependent disease (Nicholas et al., 2016). Multiple methods have been developed, but 
interpretation and comparison between studies and laboratories is difficult (McAuliffe et 
al., 2004; Pinho et al., 2012; Nicholas et al., 2016).  
Older techniques are still in use, and are especially useful as methods to compare novel 
techniques with previous studies (Pinho et al., 2012). Examples of such techniques are 
amplified fragment length polymorphism (AFLP) analysis, a DNA fingerprinting 
technique based on PCR that generates band profiles via selective amplification of 
restriction fragments of the whole genomic DNA, random amplified polymorphic DNA 
(RAPD) analysis, which uses short primers that by use of PCR amplify different fragments 
of the genome which are then separated and visualized by gel electrophoresis, and pulsed 
field gel electrophoresis (PFGE), which uses a restriction enzyme to digest the DNA, 
followed by a separation of the fragments using two alternating electrical fields. AFLP, 
RAPD and PFGE were compared in a large scale study on strains from the UK, with AFLP 
and RAPD showing the best congruence (McAuliffe et al., 2004). PFGE has been used often 




in past studies, but is being replaced by other methods due to its time-intensive, 
specialized and costly methodology and low level of discrimination between strains 
(Pinho et al., 2012). Insertion sequence typing (IS typing) is another, more discriminating, 
typing technique using mobile genetic elements (insertion sequences) present in M. bovis’ 
DNA (Miles et al., 2005; Aebi et al., 2012). In general, all of the above techniques are very 
hard to reproduce and lab-specific, making comparison difficult (Pinho et al., 2012).  
After the full genome of M. bovis was sequenced, multiple new methods were developed 
based on this information (Pinho et al., 2012). Multilocus Sequence Typing (MLST) is one 
of those methods, detecting single point mutations in housekeeping genes to compare and 
determine the relationship between M. bovis strains (Register et al., 2015; Rosales et al., 
2015). This technique is repeatable and protocol is the same between laboratories, 
making it a possible candidate for worldwide application. Two different protocols have 
been proposed using different housekeeping genes (Register et al., 2015; Rosales et al., 
2015), with the one by Register et al. (2015) being used as the reference protocol for the 
PubMLST database. However, this protocol was recently shown to be of limited use, as 
one of the targeted housekeeping genes was shown to be absent in an important part of 
the M. bovis population, making differentiation between strains very difficult 
(Communication at the ruminant meeting of the International Organization for 
Mycoplasmology, Portsmouth, 2018). Multiple-locus variable-number tandem-repeat 
analysis (MLVA) is another technique, based on the full genome of M. bovis PG45, using 9 
different tandem-repeat sequences to compare genetic microvariations, with results 
comparable to RAPD and PFGE and generally more discriminating then MLST (Pinho et 
al., 2012; Sulyok et al., 2014; Becker et al., 2015). Matrix-assisted laser desorption 
ionization-time of flight mass spectrometry (MALDI-TOF) is an upcoming technique, 
capable of rapidly identifying bacteria after isolation (Pereyre et al., 2013). Whereas this 
technique is mainly used for species identification, prospective studies have shown that 
strain typing to subspecies level might be possible, but further research is needed on this 
topic (Pereyre et al., 2013; Becker et al., 2015).  
Studies have shown that M. bovis strains derive from multiple genetic clusters. In a study 
on 54 strains collected from respiratory disease in Great Britain over 6 years, McAuliffe 
et al. (2004) saw two distinct genetic clusters using RAPD and AFLP, and a lot of variability 
in between strains. These findings were confirmed more globally with IS-typing and MLST 




by others (Miles et al., 2005; Rosales et al., 2015). Within a country, clusters may exist as 
well, and in countries with low M. bovis circulation, a single strain might be the cause of 
multiple outbreaks, such as in the Austrian Alps M. bovis outbreak from 2009-2011, where 
96.8% of the isolated strains had the same profile using both RAPD and MLVA (Spergser 
et al., 2013). Using MLST, Lysnyansky et al. (2016) found that 60% of all mastitis 
outbreaks in Israel between 2004-2014 were caused by a single strain, with a rise in 
genetic variability in recent years, possibly related to import. The same difference in 
genetic composition between strains was seen by Amram et al. (2013) when comparing 
strains from imported calves suffering from pneumonia and mastitic cows. A study by 
Becker et al. (2015) comparing M. bovis isolates obtained during a 35 year period by use 
of MLST, MLVA and MALDI-TOF MS found with all three techniques two clusters as well, 
separated in time. More recent strains (isolated after 2000) had a reduction in the 
diversity of the isolates, indicative of a single clone spreading throughout the country, 
possibly related to acquired antimicrobial resistance that emerged in the same timespan 
(Gautier-Bouchardon et al., 2014; Becker et al., 2015). Within a farm, there is a tendency 
for only one genetic profile to be present (McAuliffe et al., 2004; Aebi et al., 2012; Sulyok 
et al., 2014). However, this might be influenced by the degree of herd movements: 
whether cattle is purchased, traded or temporarily removed from the farm (eg. trade 
shows, heifer rearing) might influence the number of strains present at any given time 
(McAuliffe et al., 2004). Sulyok et al. (2014) also reported finding only one M. bovis strain 
in farms when comparing them with MLST. However, when using a more discriminating 
method (MLVA), within-farm strain differences were seen, indicating the possibility of 
closely related strains circulating within a farm.  
Strain typing by use of whole genome sequencing such as suggested for other pathogens 
might prove possible in the future. This would be a more discriminating method 
compared to for example PFGE in M. bovis strain typing as well. (Salipante et al., 2015; 
Wise et al., 2001).  




6. TREATMENT AND THERAPY FAILURE 
6.1. ANTIMICROBIAL TREATMENT 
In the past, it has been stated that mycoplasmosis is resistant to treatment with any 
chemotherapeutical agent (Pfützner and Sachse, 1996). Especially Mycoplasma mastitis is 
seen as a cause for culling and treatment is strongly discouraged (Pfützner and Sachse, 
1996; Nicholas et al., 2016). Some classes of antimicrobials (mainly macrolide and 
phenicol derivates) were however shown to have significant effect on the reduction of M. 
bovis induced respiratory disease and weight loss when used in experimental settings or 
field experiments (Godinho et al., 2005; Catry et al., 2008; Bartram et al., 2016; 
Lysnyansky and Ayling, 2016). Antimicrobial treatment of otitis media has even shown to 
result in a clinical recovery rate of 75% (Gosselin et al., 2012). Until vaccines are available, 
the use of antimicrobials is the only possible intervention after introduction of M. bovis 
into the herd.   
Only a few classes of antimicrobials have a known bactericidal effect on M. bovis, namely 
the (fluoro)quinolones and (at high doses) the aminoglycosides such as neomycin and 
gentamicin (Lysnyansky and Ayling, 2016). All other antimicrobial classes are 
bacteriostatic, slowing growth to allow the body to kill the bacteria (Lysnyansky and 
Ayling, 2016). Following recent guidelines concerning the overuse of antimicrobials in 
veterinary medicine, fluoroquinolones should be used sparingly and only when the 
bacteria are resistant to other antimicrobials given their critically important status in 
human medicine (WHO, 2017; AMCRA, 2018). Spectinomycin, florfenicol and 
tulathromycin were shown to have an effect on M. bovis induced pneumonia in 
experimental studies or field trials (Poumarat et al., 2001; Godinho et al., 2005; Catry et 
al., 2008). Of these, florfenicol is seen as the first treatment choice in Belgian national 
guidelines (AMCRA, 2018). As such, this agent should be used first, with as a second choice 
chlortetracycline, doxycycline, oxytetracycline, tilmicosin, tulathromycin or tylosin 
(AMCRA, 2018). 
6.2. ANTIMICROBIAL RESISTANCE 
Due to the absence of a cell wall, M. bovis is naturally resistant to all β-lactam 
antimicrobials (Chernova et al., 2016). Next to this, M. bovis does not synthetize folic acid, 
which means antimicrobial products of the sulfonamide class will not be effective 
(Maunsell et al, 2011). Further innate resistance for polymyxins, trimethoprim, nalidixic 




acid and rifampicin has been described for other mycoplasmas (Lysnyansky and Ayling, 
2016). Even when using a supposedly effective antimicrobial, therapy failure happens 
often, due to multiple reasons (Bushnell, 1984). As mentioned above, M. bovis has the 
capacity to “hide” intracellularly, effectively evading antimicrobials (Burki et al., 2015). 
Due to the chronic nature of the lesions induced by M. bovis, the bacteria are able to “hide” 
in the necrotic lesions as well, making it hard for the administered antimicrobials to reach 
the site of infection (Kleinschmidt et al., 2013). Furthermore, in recent years, more and 
more loss of antimicrobial susceptibility has been reported (Ayling et al., 2014; Gautier-
Bouchardon et al., 2014).  
The rise of (multi)resistant bacteria is a major concern worldwide (WHO, 2017). The 
development of antimicrobial resistance in M. bovis seems to be mainly related to 
mutations in chromosomal genes (Lysnyansky and Ayling, 2016). Different techniques 
have been described for antimicrobial susceptibility testing such as microbroth dilution, 
agar dilution and diffusion, flow cytometry and E-tests. In recent years DNA testing has 
become available, checking the presence of different loci predisposing for antimicrobial 
resistance (Gautier-Bouchardon, 2018; Sulyok et al., 2018). Currently, microbroth 
dilution methods are still used as the main method of susceptibility testing of Mycoplasma 
spp., usually based on guidelines set out by Hannan (2000). The determination of MIC 
values through microbroth dilution methods is time consuming and specialized, making 
it hard to perform in a routine fashion, and different laboratories often use different media 
or color indicators making comparison between studies difficult (Sulyok et al., 2018). A 
novel real-time PCR molecular assay developed by Sulyok et al. (2018) seems promising, 
detecting mutations on genome level responsible for elevated MICs of fluoroquinolones, 
tetracyclines, aminocyclitols, macrolides, lincosamides, phenicols and pleuromutilins in 
M. bovis. This technique could reduce the time to produce a susceptibility profile from 
weeks to 3-4 days after initial isolation of the bacteria.  However, having genetical 
markers for resistance does not always effect in a phenotypical resistance, and this 
technique will only work for these markers already identified. 
Antimicrobial resistance of a certain bacterium is often hard to define. Two main criteria 
are used to distinguish between susceptible and resistant bacteria: the use of clinical 
break points, and the use of epidemiological cutoff values (Dung et al, 2008; Schwarz et 
al., 2010). Clinical breakpoints, as set by the Clinical and Laboratory Standards Institute 




(CLSI) or the Veterinary Subcommittee on Antimicrobial Susceptibility Testing (VetCAST) 
are therapeutic breakpoints, based on in vitro tests, pharmacokinetic data, in vitro 
resistance markers, outcomes of clinical studies and other results (Dung et al., 2008; 
Maunsell et al., 2011; Toutain et al., 2017). They are used to predict the therapeutic 
success of a certain antimicrobial to a certain bacterium, dividing the tested strains into 
sensitive, intermediate and resistant categories. Sadly, no CLSI or VetCAST clinical 
breakpoints are available for veterinary Mycoplasmataceae to this date (Rosenbusch et 
al., 2005; Maunsell et al., 2011; Toutain et al., 2017). The microbiological or 
epidemiological cutoff is another criterion, distinguishing between strains which are part 
of the “wild type” population, and those which have acquired resistance to the 
antimicrobial tested by evaluating the distribution of the determined susceptibility levels 
graphically (Dung et al., 2008; Schwarz et al, 2010).  
The determination of minimum inhibitory concentrations (MIC) will give an indication of 
the in vitro susceptibility of the tested strain, but this might not be directly related to the 
in vivo susceptibility and the subsequent possibility of therapeutic success (Nicholas and 
Ayling, 2003; Schwarz et al, 2010). Even though there are no clinical breakpoints available 
for M. bovis, several studies have aimed to determine the susceptibility of M. bovis strains 
to various antimicrobials, and have used various methods to attempt to interpret which 
drugs strains were in vivo resistant to, and which drugs were still recommended for 
treatment (Ayling et al., 2014; Gautier-Bouchardon et al., 2014; Heuvelink et al., 2016). 
In Europe, even before 2000, tetracycline and macrolide resistance was already reported 
(Gautier-Bouchardon, 2018). The overall antimicrobial susceptibility of M. bovis to 
commonly used veterinary antimicrobials was found to be diminishing when compared 
to older strains as well, both in France, Great Britain and the Netherlands (Ayling et al., 
2014; Gautier-Bouchardon et al., 2014; Heuvelink et al., 2016). Interestingly, the 
antimicrobial susceptibility of M. bovis seems to vary between countries (Klein et al., 
2017). In the Netherlands, fluoroquinolones, tulathromycin and oxytetracycline were 
suggested to still be the most efficacious (Heuvelink et al., 2016). In France however, 
tulathromycin and oxytetracycline were among the antimicrobials with the highest 
increase in MIC50 and were even interpreted as being completely impotent against all 
strains tested (Gautier-Bouchardon et al., 2014). Strain sensitivity in Israel was different 
between native and imported M. bovis strains in a study by Gerchman et al. (2009), 




indicating country specific selection pressure as well. Due to the absence of clinical 
breakpoints, it is possible that strains interpreted as being resistant will still have a 
clinical effect: for example, when tulathromycin was used to treat clinical disease caused 
by a strain (M. bovis isolate 956, originally isolated from a BRD case in Italy) that tested 
apparently resistant in vitro, a detectable impact could still be seen in some cases in a 
study conducted by a pharmaceutical company (Bartram et al., 2016).  
M. bovis seems to adapt quickly to antimicrobial selection pressure, as illustrated by its 
resistance to the first choice antimicrobials in multiple countries (Gautier-Bouchardon et 
al., 2014; Heuvelink et al., 2016). Furthermore, resistance was shown to be predilection 
site dependent. For example, pneumonia strains showed a higher MIC to tulathromycin, 
an antimicrobial only indicated to treat respiratory disease, compared to strains isolated 
from mastitis lesions in one study (Heuvelink et al., 2016; Gautier-Bouchardon, 2018). 
However, in a small British study, this was the opposite, finding mastitis strains to be more 
resistant compared to respiratory strains (Ayling et al., 2014).  
Generally, given the chronicity of M. bovis induced lesions, the intrinsic resistance against 
several antimicrobials and the rise in MIC values of other antimicrobials, prevention of M. 
bovis induced disease would be much more effective than antimicrobial use. However, on 
an industrial scale, the rapid use of antimicrobials to rein in a pneumonia outbreak might 
be necessary to reduce losses, with the understanding that it will likely not result in a 
100% cure rate (Nicholas and Ayling, 2003).  
6.3. INTERACTION OF M. BOVIS WITH OTHER THERAPEUTIC AGENTS 
Dexamethasone was shown to have a positive effect on edema reduction and reinitiating 
milk production when used in cases of mastitis. However, the effect proved only 
temporary, and a more severe remission was seen after halting treatment (Bushnell, 
1984). Even more, dexamethasone administration was shown to increase shedding of M. 
bovis in calves and to have a synergistic immunosuppressive action combined with M. 
bovis (Alabdullah et al., 2015; Alabdullah et al., 2018; Calcutt et al., 2018).  
  




7. PREVENTION AND CONTROL 
As illustrated in the previous chapter, therapy of M. bovis induced disease is difficult and 
often fails. Prevention of the disease and control of spread in affected farms should be the 
primary focus. 
7.1 VACCINATION 
Multiple research groups have tried, with little avail, to create an effective vaccine to 
protect herds against M. bovis or to reduce the damage of M. bovis induced disease 
(Pfützner and Sachse, 1996; Nicholas et al., 2002; Maunsell et al., 2009; Mulongo et al., 
2013; Dudek et al., 2016). Even though small scale experiments often seem to have 
protective effect reducing gross pathological lesions and increasing M. bovis specific 
antibody titers, large scale studies of commercially available vaccines have shown no- or 
little protection or even an increase of lesions caused by M. bovis in vaccinated animals 
(Nicholas et al., 2002; Maunsell et al., 2009; Soehnlen et al., 2011; Mulongo et al., 2013). 
Strain differences and the variable expression of Vsps could explain this limited efficacy 
(Dudek et al., 2016). The variability in the expression of the Vsps poses a big difficulty, as 
they are on the one hand very immunogenic, making them an ideal candidate for use in a 
vaccine, but on the other hand, because of their variable expression, Vsp based vaccines 
might not stay effective for long (Lysnyansky et al., 1999; Perez-Casal et al., 2017). 
Research focused on the use of conserved recombinant proteins instead of bacterin 
vaccines is now developing, in the hope of providing better results in large-scale trials 
(Perez-Casal et al., 2017). Autogenous vaccination, where a herd-specific strain is 
inactivated and used in the same herd, might be a small scale solution in closed herds, but 
will have limited success in herds with frequent intermingling such as feedlots and 
efficacy might be short lived, due to the frequent changes in the Vsps (Perez-Casal et al., 
2017). Live-attenuated vaccines have shown promise as well, but will need further in-
depth research before they can be implemented on large scale (Zhang et al., 2014). 
As long as vaccine-based protection is unavailable, current M. bovis management 
programs should be based on the control of present infections and the prevention of M. 
bovis spread in and between herds.  
7.2 PREVENTION OF INTRODUCTION 
Especially M. bovis free herds should try to abstain from purchasing cattle as this is the 
largest risk factor for introduction of the bacteria (Maunsell et al., 2011). If cattle are 




purchased, a quarantine period should be respected, during which testing of the 
purchased animals is advised through serology, nasal swabs or milk analysis (González 
and Wilson, 2002; González and Wilson, 2003). In the case of dairy herds, analysis of 
multiple BTM samples of a prospective herd before purchase might be prudent as well 
(Maunsell et al., 2011). When a previously uninfected herd is found to be positive, 
stamping out policies have been tried before (Pfützner and Sachse, 1996). However, the 
success of these hinges on how early M. bovis was detected.  
Next to purchase, the removal and subsequent reintroduction of animals into herds such 
as in the case of trade shows, off site rearing, summer grazing etc. should be seen as a risk. 
Purchase or introduction of any biological materials which could be a carrier of M. bovis 
(eg. milk, colostrum, faeces, AI semen, embryos) into negative herds should be avoided as 
well, due to its inherent infective potential. Furthermore, due to the persistence of the 
bacteria in the environment, all farming equipment and transportation devices used on 
multiple farms need to be disinfected thoroughly before introduction. Lastly, herd visitors 
in contact with multiple farms or cattle derived from multiple farms such as veterinarians, 
milk truck drivers, animal merchants etc. and all fomites in contact with animals 
(medication, clothing, sampling devices, …) should be seen as a hygienic risk.  
7.3 CONTROL MEASURES ON AFFECTED FARMS 
On dairy farms, due to its chronicity, treatment failure and the possible presence of 
shedders, many authors have advised to cull all animals that test positive for M. bovis on 
culture or PCR (González and Wilson, 2003; Nicholas et al., 2016). Bulk tank milk testing 
can be used as a screening method. When the tank tests positive, identification of the 
shedders should be attempted (González and Wilson, 2003). Since subclinically affected 
cattle often have a high SCC and a decreased milk production, these cows need to be 
looked at closely, combined with recently calved cows and clinical mastitis cases 
(Maunsell et al., 2011; Al-Farha et al., 2017; Timonen et al., 2017). If culling is not an 
option, affected animals need to be separated from the normal milking herd and milked 
last, while respecting rigorous hygienic measures (Punyapornwithaya et al., 2012). 
However, in the hospital pen, the introduction of M. bovis positive cows can lead to an 
increase in transmission of the disease, possibly leading to even more animals getting 
infected and becoming carriers (Punyapornwithaya et al., 2011). Milking hygiene and 
especially individual udder preparation is of utmost importance to prevent the spread 




during the milking process. Gloves should be worn while milking, disinfecting them 
between animals (Jasper, 1982; Bushnell, 1984). Teats should be dipped with 1% iodine 
or commercial teat dip after cleaning (to remove biologic and organic materials), and 
milking equipment should be disinfected after each turn by backflushing or disinfection 
of the teat cups with spray washing or rinsing with sanitizer (González and Wilson, 2003). 
Housing in poorly ventilated barns, and having calves and adult cattle housed together, 
seems to predispose for more mastitis cases, especially when at least a group of animals 
is suffering from respiratory disease as well (González et al., 1992; González et al., 1993).  
To prevent the spread of M. bovis to young calves, several preventive measures can be 
taken. Since milk was shown to be a prime carrier of M. bovis, calves should preferably be 
fed with milk replacer or pasteurized milk in herds suffering from M. bovis disease 
(Bennett and Jasper, 1978; Walz et al., 1997; Maunsell et al., 2012). In any instance, waste 
milk or milk from mastitic cows should not be fed to calves (González and Wilson, 2003). 
Tank milk can be pasteurized at 65°C for 1 hour to effectively eliminate the threat of 
transmission (Butler et al., 2000).  Acidification of milk to a pH of 4 or lower for at least 1 
hour also effectively inhibited M. bovis growth, but this treatment might cause other 
practical problems such as reduced palatability, incubation time and separation of the 
milk in fractions (Parker et al., 2016).  
Colostrum has been called a M. bovis infection source as well, but there has been no 
definite proof of this (Walz et al., 1997; Godden et al., 2006). Pasteurization can 
decontaminate colostrum, and commercial gamma irradiated colostrum is available as 
well (Godden et al., 2006). Care should be taken to not overheat the colostrum, as the 
antibodies present within are heat sensitive (McMartin et al., 2006). Pasteurization of 30-
60 minutes at 60°C is effective to kill all M. bovis present, without a discernable effect on 
the immunoglobulin G (IgG) content, but the consistency will be altered (Godden et al., 
2006; McMartin et al., 2006). Lyophilized colostrum can be used as an alternative, if a high 
enough total amount of immunoglobulins is provided (Klobasa et al., 1998).  
Individual housing is another very effective measure to avoid rapid spread of M. bovis 
between calves through nose-nose contact (Caswell et al., 2010; Maunsell et al., 2011). For 
individual housing, it is imperative to prevent contact between calves (eg. by housing 
them in calf igloos) and to not swap feed or milk buckets between animals. Since aerosols, 
lack of ventilation and overcrowding of stables were also shown to be possible infection 




sources or predisposing factors, housing outside might be preferable (Maunsell et al., 
2011). In group housing, an all-in all-out approach is preferred, since this will prevent 
contact between the younger, more sensitive calves and the older calves (Nicholas and 
Ayling, 2003). Chronically infected calves, growth stunted calves and especially clinically 
ill animals (eg. with a head tilt, fever, runny nose or arthritis) should not be housed 
together with healthy animals to prevent the spread of M. bovis in the herd (Maunsell et 
al., 2011). Chronically ill cattle should be separated and closely followed, if they do not 
put on weight, euthanasia should be considered as an option to safeguard animal welfare 
and reduce infection pressure (Caswell et al., 2010). The prognosis for chronically 
infected calves is poor: Caswell et al. (2010) noted a positive predictive value of 50-75% 
for euthanasia at the time of entry into the chronically infected pen. 
As M. bovis can stay present in the environment for days to months, disinfection of the 
environment should be considered when dealing with an outbreak (Pfützner, 1984; 
Justice-Allen et al., 2010). In the case of bedding sand, use of 0.5% sodium hypochlorite 
or 2% chlorhexidine was sufficient to completely kill all M. bovis present (Justice-Allen et 
al., 2010). Also heat and other commonly used disinfectants such as chlorine-, acid- or 
iodine based disinfectants are effective against M. bovis (Maunsell et al., 2011). M. bovis is 
sensitive to desiccation, even though biofilm formation might be protective (at least in 
part), so leaving the disinfected pens to dry out might further reduce environmental M. 
bovis contamination (Justice-Allen et al., 2010; Bürki et al., 2015).  
  




8. RESEARCH GAPS 
Currently, the absence of an effective vaccine is seen as one of the biggest problems in M. 
bovis prevention. However, due to the chronic nature of the disease and the presence of 
shedders, this is not the only problem we are faced with. Some of M. bovis’ disease 
presentations and subsequent possible shedding sites might have been neglected in the 
past, which is especially important when looking at closed herds or areas with no to little 
M. bovis circulation. Due to the increase in global trade and the amount of bovine related 
products traded between farms (eg. AI semen, embryos, second hand machinery), the 
infectious potential of these products needs to be evaluated. Furthermore, the uncertainty 
concerning a possible aerogenous spread, environmental spread or spread through water 
should be elucidated as well. In general, focus should lay on the prevention of disease, as 
such, the identification of more risk factors predisposing for disease or spread of M. bovis 
are sorely needed. This also encompasses the determination of infectious doses for 
various infection routes.  
Updated, generalized European prevalence data should be determined for M. bovis 
pneumonia and mastitis alike, to be able to monitor the risk of importing cattle from a 
specific country. To reduce and manage the disease and its impact on farm economics and 
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In the last decades, the apparent increased incidence and spread of Mycoplasma bovis into 
previously naive countries has worried the scientific community. More recently, the 
enormous economic burden, large impact on antimicrobial use and reduced animal 
welfare have alarmed farming communities, veterinarians and governments as well. 
Mycoplasmosis has been extensively described, but a lot of research gaps in M. bovis’ 
epidemiology and predilection sites still remain. Information on national prevalence data 
is lacking as well. Given the absence of an effective treatment or vaccine, prevention of 
further spread of the disease is a key priority. Therefore, the overall objective of this 
doctoral thesis was to fill in gaps in the current knowledge of M. bovis’ epidemiology, its 
predilection sites and possible routes of transmission. 
 
The specific objectives of the present thesis were:  
(1) To determine the prevalence of M. bovis in Belgian dairy farms, and to identify herd 
level-risk factors associated with a positive bulk tank milk sample (Chapter 3) 
(2) To gain insight on the link between M. bovis and colostrum (Chapter 4), by assessing 
the survival of M. bovis in colostrum through freezing (Chapter 4.1) and by 
determining the prevalence of M. bovis DNA in colostrum samples (Chapter 4.2). 
(3) To describe a new predilection site, seromas, and to use molecular typing techniques 
to assess within animal and between herd spread of the causal strain (Chapter 5) 
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Mycoplasma bovis is an important cause of pneumonia and mastitis in cattle throughout 
the world, often reported as emerging. In absence of an effective vaccine for M. bovis, 
current prevention and control strategies rely on the identification of risk factors for 
within and between herd spread.  The objective of this study was to determine the 
prevalence of M. bovis in Belgian dairy herds and to identify risk factors associated with a 
positive PCR and/or Ab ELISA bulk tank milk (BTM) test. 
A cross-sectional study was performed in 2016 on 100 dairy farms, analyzing the BTM 
using PCR and antibody ELISA. Information on herd level risk factors focusing on 
biosecurity and management were collected through a questionnaire and sourced from 
the national herd identification system (SANITRACE). Multivariable logistic regression 
was used to identify herd-level risk factors for the presence of M. bovis DNA and 
antibodies in the BTM. The apparent prevalence on BTM was 7% and 17% for PCR and 
antibody ELISA, respectively. The true prevalence was 7.1% (95% Confidence interval 
(CI): 2.1-11.5%) and 24.8% (95% CI: 16.4-33.2%). There was no overlap between ELISA 
and PCR positive farms, resulting in a combined true prevalence of 31.8% of the Belgian 
farms being in recent contact with M. bovis.  
Risk factor analysis showed that herds with a breeding bull (M. bovis positive results for 
45.5 % and 13.6% of herds with and without a bull respectively, odds ratio: 4.7 (95% CI: 
1.1-19.8)) and without a calving pen (M. bovis positive result in 52.4% and 20.6% of the 
herds without and with a calving pen, respectively, odds ratio: 3.7 (95% CI:1.06-12.5)) 
had higher odds to harbor M. bovis antigen or antibodies in the BTM. In conclusion, the 
present study points to a several fold increase in the prevalence of M. bovis in Belgian 
dairy herds. The importance of the breeding bull and calving pen in the between- and 
within-herd spread of M. bovis might have been underestimated in the past. Focusing on 
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Mycoplasma bovis is the Mycoplasma species with the highest economic impact in cattle 
(Nicholas and Ayling, 2003). Highly contagious, it can cause a variety of clinical 
presentations of which (chronic) pneumonia, arthritis and otitis in calves and mastitis and 
pneumonia in adult cattle are the most common (Maunsell et al., 2011).  
Historically only culture has been available to assess the prevalence of M. bovis (Sachse et 
al., 1993). The development of commercial antibody (Ab) ELISA and PCR tests has 
facilitated further M. bovis screening in animals. Ab ELISA and PCR have been validated 
for use on bulk tank milk (BTM) and composite milk samples, serving as an easy to use 
indicator for the presence of M. bovis in a herd. (Cai et al., 2005; Nielsen et al., 2015; Parker 
et al., 2017). The sensitivity and specificity of a commercially available ELISA (Bio-X BIO 
K 302, Bio-X Diagnostics, Rochefort, Belgium) on BTM is estimated to be 60.4% (95% CI: 
37.5-96.2) and 97.3% (95% CI: 94-99.8) respectively (Nielsen et al., 2015). Approximately 
30% of the lactating animals in a herd need to produce antibodies against M. bovis before 
the BTM sample will test positive on ELISA (Petersen et al., 2016). After a clinical outbreak 
the antibodies stay present in BTM for about 8 months (Parker et al., 2017). PCR has a 
higher sensitivity, but relies on the active excretion of M. bovis (Sachse et al., 2010). As M. 
bovis may be shed intermittently, and the milk of mastitic cows is supposed to be withheld 
from the BTM, this could lead to an underestimation of the M. bovis herd prevalence when 
relying solely on a single PCR analysis (Petersen et al., 2016).  
Current approaches for M. bovis control are highly variable and based on the available 
knowledge of M. bovis spread (Maunsell et al., 2011). Between herds, the biggest M. bovis 
introduction risk is attributed to the purchase of carrier animals. Between adult animals, 
the milking process and direct contact are seen as the main causes of transmission 
(Maunsell et al., 2011). In calves, feeding of milk from infected cows (such as feeding 
waste milk) is seen as an important cause (Maunsell and Donovan, 2009). Other causes of 
transmission such as via fomites, airborne or aerosol spreading and colostrum have been 
suggested (Godden et al., 2006; Gille et al., 2016; Calcutt et al., 2018). Recently, infected 
semen was linked to the introduction of M. bovis into two closed herds (Haapala et al., 
2018). Elimination of M. bovis is very difficult to impossible. Especially in the case of M. 
bovis mastitis, experts urge to separate and cull affected cattle instead of trying to treat 
(González and Wilson, 2003; Fox et al., 2005; Nicholas et al., 2016). Since treatment 
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options are limited, prevention on herd and cattle level alike is key. Given the current lack 
of a useable vaccine (Perez-Casal et al., 2017), prevention hinges on the identification and 
elimination of epidemiological risk factors for M. bovis infection. Unfortunately, only a 
limited number of risk factors have been identified to this date. Having a larger herd size 
showed a strong association (15 times higher odds) with having mycoplasma in the BTM 
(Thomas et al., 1981). In the same study, a small association was also observed between 
a high culling rate and a positive BTM was seen. González et al. (1992) however, could not 
find an association between herd size and mycoplasmal mastitis. A study by Burnens et 
al. (1999) found only the purchase of animals was significantly linked to the serological 
M. bovis status of a herd (OR: 10.8). Aebi et al. (2015) found that farms applying 
forestripping, having a high average milk production or a lot of herd movements had 
higher odds of having M. bovis present. The objectives of this study were to investigate the 
prevalence of M. bovis in dairy herds in Belgium by determining the presence of M. bovis 
DNA and antibodies in BTM samples and to identify risk factors for a positive BTM sample. 
MATERIALS AND METHODS 
A cross-sectional study was conducted on 100 dairy herds in Flanders (Belgium) in 
January 2016. The study population was randomly selected (aselect procedure in 
Microsoft Excel) from the national cattle identification database (SANITRACE, animal 
health service Flanders). The herd selection was stratified on province according to cattle 
density. Sample size calculation was done through WIN EPISCOPE (Win Episcope 2.0, 
Zaragoza, Spain). A sample size of 97 herds was calculated from the pool of approximately 
6600 Flemish dairy herds (Belgium, 2016), using a worst case M. bovis prevalence of 50%, 
with 80% power and 95% confidence. BTM samples were collected during routine milk 
sampling by the Flemish milk control center (MCC-Vlaanderen) over the course of January 
2016. All farms currently not enrolled in the milk quality control program of MCC were 
automatically excluded from this study. In 2016, 4628 dairy herds were enrolled in the 
program, where 6597 herds in total produced milk in Flanders (Belgium, 2016, MCC, 
2016). Samples were cooled (4-8°C) and immediately transported to the laboratory for 
analysis. 
 







Table 1: Questionnaire provided to the farmers to gauge the internal and external biosecurity and 
general herd management concerning M. bovis: Overview on the data collected by questionnaire.  
All questions were yes vs. no questions unless otherwise specified between brackets. 
Subject Description 
M. bovis exposure Previous positive tests on the farm; Known colleagues with problems  
Herd movements/ 
Exposure to other herds 
Trade show visits; Calf rearing expedited; Neighboring pastures with cows; Use 
of farming machines from other herds; Use of farming equipment from other 
herds; Trading of bulls between farms; Distance to nearest neighbor herd (in m); 
Months of pasture access for young stock, heifers, cows; Use of a purchase 
protocol (blood testing); Use of a quarantine period (Yes, >2 weeks/ Yes, 
maximum one week/ No) 
Environmental factors Drink water type (rainwater/city water/well water) 
Hygienic measures  Herd visitors (farm specific clothing/ farm specific boots/ boot disinfectant/ 
disinfection of car/ none); Bird control measures; Rodent control measures; 
Cleaning of calf pens (removal of straw and feces/ high pressure cleaning/ 
disinfection); Separate calving pen (Yes, one cow at a time/ Yes, multiple animals 
at a time/ No); Use of calving pen by sick animals  
Calf rearing and internal 
biosecurity 
Use of milk of another herd for calf rearing; Use of colostrum of another herd; 
Use of lyophilized colostrum; Use of gamma-irradiated colostrum; Calf disease 
representation in the last year (Cough/ head tilt/ arthritis/ umbilical infections/ 
diarrhea/ pneumonia/ none of the above); Colostrum providing (Bottle/ tube/ 
suckling); Individual housing (Igloo inside/ igloo outside/ individual box in a 
separate young stock stable/ individual box in adult stable); Milk (cow’s milk/ 
powder milk/ suckling calves); Age of grouping (in weeks); Group housing 
(outside/ box in young stock stable/ box in stable of adult cows); Use of an 
automatic milk feeder; Calf contact when individually housed; Individual 
drinking buckets ; Contact of calf caretaker with adult cows  
Herd visitors Amount of visiting veterinarians; Frequency of livestock-dealer visits (in weeks); 
Visits by people also visiting veal farms  
Reproduction Use of a breeding bull ; Use of a teaser bull   
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Commercially available real-time PCR (PathoProof Mastitis Complete 16 PCR assay, 
Thermo Fisher Scientific, Finland) and M. bovis antibody ELISA (BIO K 302, Bio-X 
Diagnostics S.A., Belgium) were performed on the samples according to the 
manufacturer’s instructions. Specifically for the ELISA, the manufacturers’ recommended 
cutoff value of 37% OD was used to guarantee the best combination of sensitivity and 
specificity. After determining the apparent prevalence, true prevalence was calculated 
using Epi Tools (Ausvet, 2018). 
To collect information on potential risk factors, a questionnaire containing 44 questions 
related to internal and external biosecurity and general herd management was 
distributed to all farms by email (Table 1). The questionnaire was made available online 
through Google Forms. Non-responders were interviewed by telephone. All interviews 
were done by the same researcher. Interviews were conducted in the second part of 2016. 
Further herd information (mean herd size, amount of purchase, mortality) was gathered 
from the national registry of cattle movements (SANITRACE). All questionnaire data were 
put into a spreadsheet (Microsoft Excel) and transferred to SAS 9.4. (SAS Institute Inc., 
Cary, Inc.) for statistical analysis.  
To identify risk factors associated with the detection of M. bovis-specific DNA or 
antibodies in BTM, a multivariable logistic regression model was built (PROC LOGISTIC). 
The outcome variable was a PCR and/or antibody ELISA positive result. The elementary 
unit was the farm. In a first step, potential risk factors were tested univariably for their 
association with the outcome variable. After univariable analysis, variables with a P value 
of 0.10 or less were withheld for multivariable analysis. Predictors were grouped and 
recoded if an insufficiently low number of cases was present in a given category. Several 
factors could not be included in the univariable analysis due to a too low number of 
observations. Correlation between different predictors was tested with Pearsons and 
Spearman rho correlation. If the correlation was above 0.6, only the most significant 
variable was withheld for further analysis. Multivariable analysis was performed 
stepwise backwards, gradually excluding non-significant variables (P<0.05). Biologically 
relevant interactions between significant main factors were tested. Model fit was checked 
by the Hosmer-Lemeshow goodness of fit test. Significance was set at P≤ 0.05 and P≤ 0.10 
was considered a trend.   
 




Table 2: Results of univariable analysis of factors associated with an M. bovis positive test 
result on BTM: All variables with P ≤ 0.10. 
Variable Category n % Neg % Pos P-value 
Separate calving pen  No 21 47.6 52.4 0.02 
 Yes 34 79.4 20.6  
Individually housed 
calves 
No 2 0 100 0.04 
 Yes 53 69.8 30.2  
Purchase protocol used 
when purchasing cattle 
No 19 84.2 15.8 0.05 
 Yes 36 58.3 41.7  
Use of a breeding bull No 22 86.4 13.6 0.01 
 Yes 33 54.5 45.5  
High pressure cleaning of 
calf pens 
No 25 56.0 44.0 0.07 
 Yes 29 79.3 20.7  
Colostrum feeding by 
tube 
No 50 72.0 28.0 0.02 
 Yes 5 20.0 80.0  
Otitis (head tilt observed 
by farmer) 
No 50 64.0 36.0 0.10 
 Yes 5 100 0  
Purchase of cattle No 22 86.4 13.6 0.02 
 Yes 33 54.5 45.5  
Neg: negative BTM sample, Pos: PCR or Ab ELISA positive result, BTM: Bulk Tank Milk 
 
 




Prevalence and herd characteristics 
Overall, 7% (95% CI: 2.06 – 11.49%) of the farms tested positive by PCR on BTM, with a 
true prevalence of 7.1% (95% CI: 2.06-11.49%). Seventeen percent of all farms tested Ab 
ELISA positive on BTM (95% CI: 9.72 – 24.28%). The true prevalence was 24.8% (95% CI: 
16.42-33.15%) for the ELISA results. None of the farms that tested positive in PCR had 
detectable antibodies present in the bulk tank milk and none of the farms that were Ab 
ELISA BTM positive were PCR positive.  
The response rate of the questionnaire was 55% (55/100). Of these, 5 farms (9%) were 
PCR positive and 13 farms (23,6%) ELISA positive. The mean herd size of the farms that 
filled in the questionnaire was 157 (range: 62 - 460 animals), which was not significantly 
different from the target population (mean: 134) but did trend to be among the larger 
herds (G=1.93; df =53; p=0,06). 
No milk from other herds was purchased and no bulls were shared with other herds by 
any of the 55 herds. Only one herd used a teaser bull for heat detection. None of the herds 
used automated milk feeders. All calves were housed inside after weaning. All of these 
factors were excluded from further analysis given the low number of observations in one 
or more categories. 
Concerning biosecurity, only one of the herds applied hygienic measures to clean off 
premise vehicles. One fourth of all interviewed farmers indicated that they did not enforce 
any hygienic measures for visitors at all. When farmers used a bull for some animals, but 
not the whole herd (eg. to breed rebreeders), they were grouped in the “uses a bull for 
insemination” category. Sixty percent of the farms still used a bull on some or all cows.  
Risk factor analysis 
Due to the relatively small number of returned questionnaires, the outcome variable was 
adapted to “having a M. bovis-specific DNA or antibody positive BTM sample” instead of 
analyzing data from ELISA positive herds separately from PCR positive herds. After 
univariable analysis eight variables with a P value of 0.10 or less were withheld for 
multivariable analysis: the use of a separate calving pen, individual housing of calves, the 
use of a cattle purchase protocol (serological testing of a variety of diseases at purchase), 
the use of a breeding bull, high pressure cleaning, colostrum feeding by tube, presence of 




otitis media and purchase in the year before testing (Table 2). Purchase of cattle in the 
year before testing was significantly correlated to the presence of a bull, but the bull was 
more significantly linked to a positive sample. The final model consisted of two significant 
risk factors for a positive BTM result after multivariable analysis (Table 3). Farms which 
used a breeding bull had 4.7 higher odds to test positive. The use of a separate calving pen 
was a protective factor (OR= 0.27).  
 
Table 3: Final multivariable model for M. bovis PCR or antibody ELISA positive bulk tank 










Use of a 
breeding bull 
No 22 13.6 Ref.    
 Yes 33 45.5 4.7 1.1 - 19.8 0.04 
Separate calving 
pen 
No 21 52.4 Ref.    








This study aimed to determine the prevalence of M. bovis in Belgium, and to identify new 
risk factors. One hundred dairy farms were randomly selected, stratified on province.  
Selection bias cannot be ruled out, since herds needed to participate in the milk control 
program in order to be eligible for this study. It is possible that these herds are, in general, 
larger and possibly more modern.  In the present study a relatively high response rate of 
the questionnaire of 55% was achieved. However, this still left the study with relatively 
low power due to the initial sample size, which could mean certain risk factors remain 
unidentified. Since the questionnaire was made available online, and non-responders 
were contacted by phone, a certain measure of observer bias was possible. However, to 
mitigate this, only one researcher conducted the interviews by telephone, following the 
same questionnaire as what was made available online. Due to time constraints 
interviews were performed more than 6 months after the initial sampling. This might 
have been a cause of recall bias in the interviewees, although none indicated to have done 
a big shift in farming in the time passed. Only one sample per herd was taken, which could 
have impacted the sensitivity of this study (Biddle et al., 2003).  
In Belgium in 2009, 1.5% of all BTM samples from three consecutive samplings in 200 
herds tested positive using bacterial culture (Passchyn et al., 2012). In this study, done on 
the same sample pool in 2016, 7% of the tested herds had active circulation of M. bovis, 
detected through a PCR positive BTM sample. This seems to be a notable increase 
especially since only one sample per herd was taken. However, comparing the two studies 
is difficult due to the difference in technique. When comparing to recent studies 
determining between-herd prevalence using PCR on BTM from the Netherlands (approx. 
1% in 2017) (Hogenkamp, 2017), Denmark (1.6 % in 2015) (Nielsen et al., 2015) and the 
south-east of France (0% in 2011) (Arcangioli et al., 2011), our findings seem to indicate 
a higher active infection rate in Belgian farms compared to other closeby countries. One 
possible explanation for this higher prevalence could be the intensive contact structure 
(40% of all cattle born between 2005-2009 moved herds at least once (Ensoy et al., 2014)) 
and high geographical density of Belgian herds. In contrast to PCR, Ab ELISA does not 
detect active circulation, but can detect recent contact of a herd with M. bovis. The true 
prevalence using Ab ELISA on BTM in this study was 24.8%. Since this BTM ELISA 
technique is relatively new, only data of one other country, Denmark, is available to this 




date. Nielsen et al. (2015) found a prevalence of 7.1% in BTM of Danish herds when using 
the same test with the recommended cutoff of ODC% 37%. Comparing BTM ELISA results 
with previous serological studies on M. bovis prevalence is difficult: Parker et al. (2017) 
found a relatively low correspondence between serological results and BTM ODC%, 
suggesting a lower usability of the BTM test as a between-herd screening tool when trying 
to predict within-herd seroprevalence. Antibodies were detectable in the BTM for up to 
12 months after the initial outbreak. After this period, despite having further positive M. 
bovis culture or PCR results, the BTM ODC% dropped under the detection limit. However, 
notwithstanding these limitations, in our opinion BTM analysis can still be a valid 
between-herd screening tool in the field, for example in a purchase protocol, especially 
when combined with PCR analysis as it is practical and low cost. Previous research found 
virtually no overlap between PCR or ELISA positive BTM samples, except what could be 
explained by chance (Parker et al., 2017). This reflects our findings in the current study, 
where no overlap was seen between PCR and ELISA samples. A possible hypothesis of this 
lack of overlap is that, in newly infected herds, PCR positive samples will appear at least 
1-2 weeks before seroconversion, by which time it can be expected that actively infected 
animals have shown signs of mastitis and are separated from the BTM (Nicholas et al., 
2002). Next to this, it is possible that M. bovis antibodies are developed in response to 
other M. bovis associated diseases such as pneumonia or arthritis, without subsequent 
shedding in milk. Regardless of the test, the results in this study seem to indicate a higher 
M. bovis prevalence level compared to neighboring countries. 
One of the most interesting observations of this study was the association between the 
presence of a breeding bull and a M. bovis positive BTM sample (DNA or Ab). Moreover, 
where previous purchase was identified as a risk factor for the presence of M. bovis in a 
herd (Burnens et al., 1999), this study showed that, although purchase was part of the 
univariable risk factors, it was strongly associated with the presence of a breeding bull, 
and the breeding bull was the more significant factor of the two. Bulls are still often used 
in Belgian herds to breed with rebreeders and older cows (as a means to produce more 
valuable crossbreed calves). Next to the purchase of the bull, Belgian dairy herds are often 
closed, with year-round calving patterns.  Herd size was not significantly linked to M. bovis 
presence on the farm in this study, in contrast with the findings of Thomas et al. (1981) 
and Fox et al. (2003) but consistent with the findings of González et al. (1992). Since the 
biggest herd included in this study only had around 460 animals, it is possible that the 
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Belgian mean herd size is not big enough to be able to distinguish significant differences 
between smaller and larger herds.  Another possibility is that purchase and herd size are 
linked as well, where larger herds might buy in (or have bought) cattle more often to 
sustain their growth.   
In bulls, M. bovis colonizes the prepuce and the distal urethra (Fish et al., 1985), 
decreasing the fertility (Bielanski et al., 2000). Seminal vesiculitis, epididymitis and 
persistent infection along the seminal tract with concurrent shedding have been 
described (Kirkbride, 1987). M. bovis has been found in vaginal swabs of apparently 
unaffected cattle and cattle suffering from clinical mastitis (Punyapornwithaya et al., 
2010; Hazelton et al., 2018). It was isolated from uterine samples, out of aborted foeti and 
in postsurgical seromas after caesarean section (Stalheim and Proctor, 1976; Pfützner and 
Sachse, 1996; Gille et al., 2016). When AI was performed with M. bovis infected semen 
persistent infection of the genital tract was seen, with shedding for up to 8 months post 
AI (Hirth et al., 1966). The findings of the present study, suggesting the importance of the 
bull, combine well with a recent report of M. bovis introduction into 2 naïve herds in 
Finland by use of AI (Haapala et al., 2018). Also in the recent introduction of M. bovis in 
New Zealand, semen was a suspect of being the source of introduction (Ministry for 
Primary Industries, 2017). M. bovis in semen can survive cryopreservation for up to 18 
months (Hirth et al., 1966). The commonly used antimicrobial cocktail to decontaminate 
AI semen could be insufficient (Visser et al., 1999). Given recent observations and our 
current findings, it seems possible that the role of semen in the M. bovis epidemiology has 
been underestimated in the past. 
A second remarkable observation was the protective nature of a separate calving pen for 
the M. bovis status of the herd. There seem to be two possible explanations to this 
protective effect. On one hand, it is possible that the periparturient immunity depression 
could induce shedding of higher numbers of M. bovis at calving. However, even though M. 
bovis has been isolated out of placenta and fetal fluids, no research has been done on the 
infectious capacity of M. bovis excreted during parturition (Stalheim and Proctor, 1976). 
On the other hand, the use of a calving pen might protect the immunosuppressed 
periparturient animals from infection by limiting contact with carriers present in the 
herd. Limiting contact between susceptible animals and shedders will in any case limit 
the exposure, with concurrent less shedding in the BTM. An interesting parallel can be 
drawn between M. bovis and Chlamydia sp., as both the breeding bull and calving away 




from the herd were shown to be risk factors for the latter as well (Kemmerling et al., 
2009).  
CONCLUSIONS 
A considerable proportion of the Flemish dairy herds had recently been in contact with 
M. bovis at the time of this study. Based on PCR results, the active prevalence of M. bovis 
seems to be higher compared to studies in neighboring countries. This study identified 
having a breeding bull and the absence of the calving pen as risk factors for having an 
ELISA or PCR positive BTM sample.  Further attention should be given to the role of the 
breeding bull and calving pen in the spread of M. bovis in a herd, and their potential role 
in the development of effective control and preventive measures for M. bovis.  
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Mycoplasma bovis is an important cause of mastitis in dairy cattle, and pneumonia, 
arthritis, and otitis in calves. Milk and colostrum are considered important sources of 
infection for calves. Knowledge on the effect of on-farm freezing (−18°C) and thawing 
methods on the recovery of M. bovis from colostrum samples is missing. In this study, 2 
separate experiments were performed. The first experiment consisted of a longitudinal 
study examining the survival [as measured by log(10) reduction] of 2 M. bovis strains in 
frozen colostrum over 14 wk. The second experiment examined the effect of different 
thawing temperatures (45 and 20°C), thawing frequencies (once or twice), and initial 
colostrum titer (104 or 106 cfu/mL) on M. bovis survival. A single freeze-thaw cycle led to 
an approximate 1 log reduction of M. bovis titer, independent of the thawing temperature. 
Freezing for 14 wk did not significantly further reduce the titer of bacteria compared with 
freezing for 2 wk. A second freeze-thaw cycle further reduced the M. bovis count by 
approximately 0.5 log compared with a single freeze-thaw cycle. Thawing temperature 
and initial bacterial concentration did not significantly affect M. bovis reduction. In 
conclusion, storage of colostrum samples in the freezer at −18°C during epidemiological 
studies, herd monitoring, or test and cull programs will probably have little influence on 
qualitative bacteriological test results for M. bovis. The epidemiological or clinical 
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Mycoplasma bovis (M. bovis) has been recognized as an important cause of untreatable 
mastitis in adult cattle and chronic, unresponsive pneumonia in calves, frequently 
complicated by arthritis and otitis (Maunsell and Donovan, 2009; Maunsell et al., 2011). 
Annual losses due to M. bovis have been estimated to be above 140 million dollars in the 
US (Rosengarten and Citti, 1999). It is generally accepted that the most important way of 
M. bovis introduction into a farm consists of purchase of a carrier (Fox, 2012). Sperm can 
be infectious (Pfützner and Sachse, 1996), and recent work suggests the possibility of 
between herd spread through fomites or persons (Gille et al., 2016).  
Known routes of transmission at individual animal level are the milking process, direct 
nasal contact, semen and the consumption of infected milk (Pfützner and Sachse, 1996; 
Fox et al., 2005). For calves in particular, consumption of infected milk is believed to be 
the primary route of infection (Walz et al., 1997; Butler et al., 2000; Maunsell and 
Donovan, 2009; Maunsell et al., 2012). Relatively few studies have documented the within 
herd prevalence of M. bovis in milk samples. In a recent Swiss study the within herd 
prevalence of M. bovis shedding cows was 2.4% (95% confidence interval (CI)= 1.5-3.8) 
on milk by PCR assay (Aebi et al., 2015). In other studies a within herd prevalence 
between 2.6 and 43.0% has been reported (Fox, 2012). 
Colostrum has been mentioned as a possible source of infection as well, but the prevalence 
of M. bovis in colostrum samples is currently unknown (Godden et al., 2006). Preliminary 
PCR testing of colostrum samples at the Belgian center for milk quality control (MCC-
Vlaanderen) did identify some positive samples (personal communication, K. Supré). The 
presence of M. bovis in colostrum is currently unaccounted for in M. bovis preventive 
protocols. Indeed, the commonly recommended individual housing for 8 weeks without 
nose-nose contact, together with replacing cow’s milk by milk replacer, might have 
limited efficacy to reduce mycoplasma infection if M. bovis positive colostrum has been 
given previously (Maunsell and Donovan, 2009). Colostrum samples are often stored 
frozen prior to analysis (Godden, 2008). However, it is unknown how freeze-thaw cycles 
affect recovery of M. bovis from these colostrum samples. Freezing of milk samples has 
been shown to reduce the recovery of M. bovis by culture (Boonyayatra et al., 2010). 
Considering the different composition of colostrum compared to milk (Foley and Otterby, 
1978), simple extrapolation of the survival data of M. bovis in milk to colostrum may be 
incorrect (Boonyayatra et al., 2010).  




The objectives of the present study were to determine the effect of the duration of the 
freezing period, the number of freeze-thaw cycles and the thawing temperature on the 
survival of M. bovis in colostrum samples inoculated with two concentrations of M. bovis. 
Two separate experiments were conducted to achieve these objectives. 
The colostrum used in experiments one and two was purchased gamma irradiated frozen 
bovine colostrum (ECI, Marloie, Belgium), guaranteeing immunoglobulin levels over 70 
g/L and a sterile product. Sterility was verified by plating the colostrum on standard blood 
culture, incubated at 37°C, 5% CO2 for 24h and on Pleuropneumonia Like Organism 
(PPLO) agar (DIFCOTM, BD©), incubated for one week, to check for mycoplasmal growth 
specifically. Colostrum was thawed at room temperature before inoculation with M. bovis.  
In experiment one, the effect of the duration of the freezing period on survival of M. bovis 
in colostrum was evaluated. Two strains of M. bovis were inoculated in colostrum. At 
inoculation (T0) and after 1 (T1), 4 (T2), 10 (T3) and 14 weeks (T4) of storage at -18°C, 
three colostrum samples for each strain were thawed at 20 °C (room temperature) and 
serial culture was performed to determine the M. bovis titer.  
In experiment one, two strains of M. bovis (LG1 and LG2) were used. LG1 originated from 
a bronchoalveolar lavage sample from a calf with pneumonia, LG2 originated from a milk 
sample from a cow with mastitis, arthritis and an infected seroma (Gille et al., 2016). M. 
bovis species identification was confirmed by use of real-time PCR targeting the uvrC gene 
of filter-cloned isolates (Rossetti et al., 2010). In preparation for this study, two hundred 
microliters of a M. bovis strain suspended in a storage medium consisting of 75 ml horse 
serum (Thermo Fisher Scientific, Carlsbad CA, USA) and 25 ml Brain Heart Infusion (BHI) 
broth (Bio-Rad, Hercules CA, USA) supplemented with 10% (w/v) glucose (Merck, 
Darmstadt, Germany) was inoculated into 10 mL of modified PPLO broth (DIFCOTM). After 
inoculation, the broth was incubated for five days at 35°C and 5% CO2, after which the 
PPLO broth was centrifuged at 4500 x g for 30 minutes to sediment the bacteria. The 
supernatant was discarded and the pellet was resuspended in sterile phosphate buffered 
saline (PBS) (M: 0.1; Ph 7.4). Dilution of the bacterial suspension to approximately 1010 
CFU/mL was done by use of an optical density meter (Ultrospec III, Pharmacia Biotech, 
UK). The sample was diluted until an optical density of 0.2 absorbance units at 540 nm 
was achieved, based on specifications by Boonyayatra et al. (2010). Further dilution was 
done to achieve starting titers of 106 M. bovis CFU / mL colostrum. The inoculated 




colostrum samples were stored in sterile 15 mL Falcon® centrifugation tubes (Fisher 
ScientificTM, MA, US) and frozen at -18°C. M. bovis titer was determined immediately after 
complete thawing (no ice visible). 100 µL colostrum was plated on PPLO agar using serial 
dilutions. Samples were incubated for one week at 35°C and 5% CO2, and colonies (with 
the typical fried-egg appearance) were counted with help of a microscope (10x 
magnification). Each sample was only plated once, but for each timepoint multiple 
samples were thawed. 
To determine the effect of freezing over a 14 week period and the effect of M. bovis strain 
on the survival of M. bovis in colostrum samples a linear mixed model with repeated 
measures was used (PROC MIXED). Five time points (at inoculation (T0), after 1 week 
(T1), after 4 weeks (T2), after 10 weeks (T3) and after 14 weeks (T4)) were included as 
the within-subjects factor, strain type (LG1 vs. LG2) was added as a between-subject 
factor. The sample size (3 observations per group per time point) was based on the 
detection of a 1 log difference between both strains, with a standard deviation of 0.4 log, 
80% power and 95% certainty. Mauchy’s test of sphericity was used to determine equality 
of variances. Model validity was checked through inspection of the residuals. Bonferroni 
corrections were used for pairwise comparisons between the different time points. A 
compound symmetry repeated variance structure was used. In all models significance 
was set at P<0.05, and 0.05<P<0.10 was considered a trend. All analyses were performed 
in SAS version 9.4 (USA). 
In the second experiment, the effect of repeated thawing (once or twice) and temperature 
of the first thawing process (either 20°C (room temperature) or 45°C) on M. bovis 
recovery was determined using two inoculum titers (104 and 106 M. bovis CFU/mL). The 
sample size required to detect a 1 log reduction in M. bovis count between two 
storage/thawing methods, with 95% certainty and 80% power was 18 observations per 
group (Win episcope 2.0, Spain).  
A full factorial design was used with four test groups: (1) ST20 (single thawing 20°C) = 
freezing for two weeks, single thawing at 20°C; (2)  ST45 (single thawing 45°C)= freezing 
for two weeks, single thawing at 45°C. (3) RT45 (repeated thawing 45°C): freezing for 1 
week, thawing at 45°C, refrozen for 1 week, thawing at 20°C; (4) RT20 (Repeated thawing 
20°C)= freezing for 1 week, thawing at 20°C, refrozen for 1 week, thawing at 20°C.  




Sample preparation was identical to experiment one, except that only the LG1 strain was 
used, in titers of 104 and 106 M. bovis CFU/mL colostrum. The inoculated colostrum 
samples were split in 16 portions of 10 mL colostrum, which were distributed over the 
four treatment groups. The experiment was repeated three times. One week after 
inoculation, groups RT20 and RT45 were thawed at 20°C and 45°C, respectively, and 
refrozen at -18°C. All groups were thawed at their respective temperatures 2 weeks after 
inoculation. M. bovis titer was determined using the same method as in experiment 1. 
 
Figure 1. Mean concentration of colony-forming units per milliliter of colostrum after freezing 
and thawing a single time over a set time period. Time = 0 = inoculation; time = weeks of freezing. 
Values with different letters (a,b) are significantly different (P < 0.05) within subjects (time effect). 
Error bars represent SD.  
A linear mixed-model (PROC MIXED) was used to determine the effects of the initial M. 
bovis concentration in colostrum (104 vs. 106), number of freeze-thaw cycles (1 vs. 2) and 
thawing temperature (20°C vs 45°C). The test run was added as a random effect to account 
for clustering of measurements within a run. A maximum likelihood estimation with 
Satterthwaite approximation was used. All factors were forced into the model and 
interactions between significant main effects were tested. Post-hoc comparisons were 
made using Bonferroni corrections. Model validity checking and significance definitions 
were as described for experiment one.  
In experiment one, the effect of freezing duration on the survival of M. bovis in colostrum 
was determined. Freezing significantly reduced M. bovis concentration by a mean of 0.81-




1.02 (SD: 0.13-0.15) log for LG1 and LG2, respectively between inoculation and 1 week 
later (Figure 1). Longer freezing times did not result in further decrease in the number of 
M. bovis recovered from colostrum. No significant effect of strain was observed (Figure 1). 
Values with a different superscript were significantly different from each other (P<0.05) 
within subjects (time effect). 
 The effects of repeated thawing and thawing temperature tested in experiment two are 
shown in Table 1. Independent of the starting titer (104 or 106 CFU/mL), freezing and 
thawing of M. bovis infected colostrum reduced the M. bovis concentration by 
approximately 1 log compared to the initial concentration. Thawing temperature (20°C 
versus 45°C) did not have a significant effect on the survival of M. bovis in colostrum (P= 
0.43). Repeated thawing of colostrum further decreased the number of M. bovis by 
approximately 0.5 log compared to single thawing, regardless of the starting 
concentration of M. bovis (P<0.05).  
As expected, freezing and subsequent thawing of colostrum did not result in a complete 
elimination of M. bovis, similar to previous observations in milk samples (Boonyayatra et 
al., 2010). After a single freeze-thaw cycle, the M. bovis concentration was reduced by 
approx. 1 log, independent of the starting titer, which is comparable to the findings 
reported for milk samples (Boonyayatra et al., 2010). Unlike the aforementioned study, 
longer freezing intervals were tested in this study as well. This did not result in a 
significant further decline of M. bovis CFU. Mycoplasma concentration in milk ranges 
between 102 and 108 CFU/mL, with the vast majority above 106 CFU/mL (Biddle et al., 
Table 1. Effect of different thawing temperatures and repeated thawing on recovery of Mycoplasma 
bovis from bovine colostrum samples, with a titer of 104 or 106 CFU/mL M. bovis.   
 Low starting titer (104 CFU/mL) High starting titer (106 CFU/mL) P-value 
 Single Thaw Double Thaw Single Thaw Double Thaw     
Thawing 
Temp 





















<0.001 0.43 <0.001 0.17 
Results presented as means of 3 independently repeated experiments ± standard deviation 
*log transformed concentration 
Freq.: Thawing frequency, Temp.: Temperature, Conc.: Inoculation Concentration 
 




2003; Cai et al., 2005). If the M. bovis concentrations in colostrum and naturally infected 
milk are similar, an approximate 1 log reduction will result in M. bovis concentrations 
ranging between 10 and 107 CFU/mL colostrum. Such M. bovis concentrations can be 
detected with most of the commonly used screening methods such as PCR, ELISA and 
culture (detection limit: 10 CFU/mL (Biddle et al., 2003)). Intermittent shedding has been 
described for several Mycoplasma species, so negative results should be interpreted 
carefully (Biddle et al., 2003). 
Extension of storage time at -18°C for up to 14 weeks did not further decrease the survival 
rate of M. bovis in colostrum, as compared to storage for one week. These results further 
illustrate that long-term freezing of colostrum is not a valid control strategy to prevent M. 
bovis infection of neonatal calves. Double freeze-thaw cycles resulted in a significantly 
larger reduction of M. bovis in colostrum. Multiple freeze-thaw cycles can cause an 
undesirable decline in maternal antibody levels (Argüello et al., 2003) and are thus not 
recommended.  
In conclusion, single and double freeze-thaw cycles reduce M. bovis concentration in 
colostrum by 1 to 1.5 log respectively. Thawing temperature and initial bacterial 
concentration did not significantly affect the survival of M. bovis in colostrum. The storage 
of colostrum samples in the freezer at -18°C during epidemiological studies, herd 
monitoring or test- and cull programs likely has little influence on qualitative 
bacteriological test results for M. bovis. As there are currently no indications on the 
minimal infective dose of M. bovis in colostrum, the epidemiological or clinical relevance 
of an approximate 1 log reduction of M. bovis in colostrum is currently unclear and 
deserves further attention in future research. In case a lower M. bovis titer reduction is 
desired for epidemiological studies, addition of glycerol might be a valid aid, as described 
for milk samples by Boonyayatra et al. (2010). 
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In herds with an active Mycoplasma bovis circulation, colostrum is often considered a 
source of infection for neonatal calves. Control measures to prevent infection include the 
removal or treatment of said colostrum, causing economical and practical issues, possibly 
resulting in a suboptimal start of the calf’s life. However, to date no studies on the 
presence of M. bovis in colostrum are available. Therefore, this study aimed to determine 
the prevalence of M. bovis DNA in colostrum samples of herds with a recently confirmed 
M. bovis infection in Belgium. In total, 368 colostrum samples were collected in 2016 and 
2017 from 17 farms. Only 1.9% (7/368) of the samples tested PCR positive for M. bovis, 
with 13 out of 17 sampled herds having no detectable M. bovis DNA in colostrum. The 
within herd prevalence averaged 3.2% (standard deviation= 4.9%; Range: 0-30.0%). Only 
three samples had a Ct-value below or at 37, four others had higher Ct-value (<40), 
indicating a low concentration of bacterial DNA. In conclusion, with the PCR assays used 
in the present study, M. bovis DNA was occasionally detected in colostrum samples in 
herds with M. bovis circulation. The epidemiological relevance of this observation is 
currently unknown. The present results may indicate that in infected herds, the within 
herd transmission due to colostrum is low compared to the other ways of transmission. 
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Mycoplasma bovis strongly contributes to economically important diseases like mastitis 
and pneumonia and heavily affects animal welfare and antimicrobial use in modern dairy 
farming (Calcutt et al., 2018). Prevalence seems to be rising and increasing antimicrobial 
resistance has been reported as well (Gautier-Bouchardon et al., 2014; Gille et al., 2018b).  
The major ways of M. bovis transmission between animals are direct contact (eg. through 
respiratory secretions) and consumption of infected milk (Maunsell et al., 2011). 
Introduction into a herd usually happens through purchase of replacement animals (Fox 
et al., 2005). However, several other ways of M. bovis introduction and transmission might 
have been neglected in the past. Troubling recent illustrations are the introduction of M. 
bovis in two Finnish herds by use of contaminated artificial insemination semen (Haapala 
et al., 2018), and the first detection of M. bovis in New Zealand in July 2017 (McDonald et 
al., 2009, Ministry for Primary Industries, 2017). In the latter outbreak, import of 
embryos, feed, fomites, semen and other animal species were investigated as sources of 
this introduction, since no live cattle were imported since 2013, but to date the source 
remains unidentified (Ministry for Primary Industries, 2017). In the current mindset of 
reducing antimicrobial use and improving animal health, it is imperative to prevent M. 
bovis introduction on farms and countries alike.  
Colostrum has been mentioned as a possible source of M. bovis in the past (Godden et al., 
2006, Maunsell et al., 2012), but to the author’s knowledge, no systematic studies on the 
prevalence of M. bovis in colostrum are currently available. Despite this lack of 
information, empirically designed M. bovis herd control programs often advocate the 
removal or (heat-) treatment of the herd’s own colostrum as a precaution measure 
(Maunsell et al., 2011). Withholding colostrum from neonatal calves is not an option, as 
they depend on colostrum to bridge the period from birth until their own immunity kicks 
in (Godden, 2008). Purchase of colostrum from other herds holds a risk for other 
infectious diseases, especially paratuberculosis (Mycobacterium avium subsp. 
paratuberculosis) (Streeter et al., 1995) and will not provide the calf with herd-specific 
maternal immunity. Decontaminated colostrum (pasteurized or gamma irradiated) can 
be bought, but this will result in a significant financial burden. Heat treatment lacks, 
especially in smaller farms, economical and practical feasibility due to the small amounts 
to be processed. Knowledge on the prevalence of M. bovis in colostrum is essential to guide 




farmers in the choice of which preventive- or control measures are preferentially taken 
when considering within- and between herd spread of M. bovis. Therefore, the main 
objective of this study was to determine the presence of M. bovis DNA in colostrum from 
herds with a recent M. bovis infection. A secondary objective was to determine if a 
seasonal effect could be seen in selected herds that were followed over time.  
A survey was conducted on seventeen farms throughout Belgium. Farms were 
conveniently selected by the local veterinarian and samples were collected throughout 
2016 and 2017. The inclusion criteria were a recent (< one month) M. bovis infection in 
the herd, documented by either positive culture or PCR, and the willingness of the farmer 
to participate. Farms could be either beef, dairy or mixed type. Four beef, five dairy and 
eight mixed farms participated. Sample size calculations were preset on the available 
budget, which allowed the analysis of up to 370 samples. Based on an average herd size 
of 80 lactating animals and with an expected prevalence of 25% of the animals shedding, 
ten animals needed to be sampled in each herd to detect M. bovis with 95% confidence. A 
limit of twelve samples per herd was set on thirteen farms. Four farms were sampled for 
a longer time (six to twelve months) to determine seasonal variation and to possibly 
gather better insight on how to interpret the results in other herds. Colostrum samples 
were collected immediately post-partum after disinfection of the teats with gauze 
drenched in alcohol. A cow composite sample (pooled sample of all four quarters for each 
cow) was taken for each cow in a 15 mL Falcon™ tube (Fisher Scientific). Sample collection 
and subsequent storage at -20°C was performed by the farmer. Farmers were informed 
on the most ideal sampling procedure, and provided with the necessary material to 
perform this in a repeatable fashion. The samples in the thirteen herds that had a 
maximum of twelve samples were analyzed individually at the laboratory of ARSIA for 
presence of M. bovis DNA by real-time PCR (VetMAX™ M. bovis kit, ThermoFisher 
Scientific), targeting the uvrC gene. Before analysis, samples were mixed with PBS, 
centrifuged and the supernatans discarded. A mix of proteinase K/ATL buffer (Qiagen) 
was added to the pellet before cell lysis. DNA was automatically extracted by use of the 
MagAttract 96 cador pathogen kit (Quiagen) and KingFisher™ Flex 96 Deep-Well Magnetic 
Particle Processor (Thermo Fisher ScientificTM). All samples with a Ct below 40 were 
considered positive. 




In the case of the four herds with a longer time of follow-up, testing was performed by the 
laboratory of the Milk Control Centre (MCC) after pooling the cow composite samples. In 
the MCC laboratory, pooled samples were examined using the real-time PCR Pathoproof® 
Complete 16-kit (Thermo Scientific) according to the supplier’s manual. Each pool 
consisted of a maximum of five cow composite samples of cows belonging to the same 
herd. Because of the consistency of colostrum, one third of the pools for examination were 
analyzed in duplicate with an adapted protocol (dilution of the colostrum to 1/10 in 
sterile water and an extra 5 min incubation during the DNA-extraction). There was no 
difference in results between the two methods and as such the standard protocol was 
used. Colostrum samples of the M. bovis positive pools were examined individually the 
next day. Ct-values below 37 were considered as positive; Ct-values between 37 and 40 
were considered borderline, but positive. 
Data were kept in Excel 2016, and analyzed by SPSS version 25 (IBM, Armonk, New York, 
United States). In total, 368 colostrum samples from seventeen herds were analyzed 
(table 1). M. bovis DNA was detected in 1.9% (7/368) of these samples, positive samples 
were obtained from four different farms. Thirteen of the 17 sampled farms did not have 
any M. bovis positive colostrum samples. On the four farms that did have positive samples, 
on-farm/within herd prevalence ranged between 2.8% (2/71) and 30% (3/10). The 
average within herd prevalence was 3.2% (Standard deviation: 4.9%; Range: 0-30.0%). 
Of the seven positive samples, four samples yielded a borderline positive Ct value (>37 
and <40), probably indicating a low M. bovis DNA-content or a false positive result (Table 
2).  
To the authors knowledge, this is the first study aiming at determining the prevalence of 
M. bovis in colostrum. Because colostrum samples can only be collected at one time point 
(just after calving), the decision was made to have the sampling performed by the farmer. 
Unfortunately not all farmers complied 100% with the protocol and did not send in the 
twelve samples required for each farm to achieve the desired level of precision. Several 
PCR positive samples had a high Ct value, indicating only a marginal amount of M. bovis 
DNA present in the sample. Very high Ct values may indicate carryover of DNA between 
samples (Klaas et al., 2016). Even though all farmers were instructed to take milk samples 
as cleanly and aseptically as possible through an on-site demonstration, it is possible the 
actual sampling was not done lege artis in every case. 




The main finding of this study was that M. bovis DNA could be detected in colostrum in a 
small amount of samples. In the herds where a longitudinal follow-up was done over the 
year, only two positive samples were found on a total of 258 samples, while M. bovis was 
still circulating in the herd during the entire study (based on sampling of clinical cases). 
Because of the low amount of positive samples, no conclusions on seasonality could be 
made based on the results of these herds. The use of PCR methods that were 
manufactured for the use on milk could also have influenced the diagnostic accuracy on 
colostrum. With the PCR assays used in this study, M. bovis DNA was only sporadically 
detected in colostrum.  It is unclear whether the amount of bacteria present in colostrum 
would suffice to infect the calf, especially in the case of marginally positive samples. 
Furthermore, the viability of M. bovis in these samples was not determined in this study. 
Previous research has shown a one log reduction of M. bovis CFU/ml when colostrum was 
frozen and subsequently thawed (Gille et al., 2018a).  
Our results seem to indicate that the prevalence of M. bovis is that low that prospective 
economic damage of the within-farm transmission risk doesn’t outweigh the economic 
disadvantages of purchasing colostrum from other herds or investing in pasteurization 
equipment on already infected farms. This requires, however, confirmation in a larger 
study in which preferably different techniques are used to demonstrate the presence of 
M. bovis in colostrum, including isolation of the agent.  
M. bovis negative herds on the other hand should consider preventive measures such as 
pasteurization or gamma irradiation when buying in colostrum from other farms, to 
prevent the introduction of M. bovis in the herd. Alternatives such as on farm acidification 
(Parker et al., 2016) might be an option, but warrant further research, especially 
concerning the preservation of maternal antibodies in colostrum. Freezing and 
subsequent thawing was shown to reduce the amount of colony forming units by one log 
(Gille et al., 2018a), which could mean that, in the case of low level M. bovis contamination, 
this treatment could lessen the risk of infection. However, no infectious dose has been 
established for M. bovis yet, so any future applications should be researched further. 
Attention should be paid to avoid contamination while sampling, to avoid incorrect 
decisions to remove animals from the herd. Discarding colostrum of cattle with a known 
M. bovis infection is likely a good advice.  




A variation of colostral shedding was seen between the tested herds in this study, which 
could indicate differences in excretion of M. bovis. Hypothetically, this could be based on 
the time of introduction of M. bovis in the herd, where recently infected herds would have 
a higher amount of shedding, concurrent with the rapid spread of an M. bovis strain 
through a seronegative population (Arcangioli et al., 2008). However, herd 17 was 
experiencing a large outbreak of M. bovis related disease in adult cattle at the time of 
sampling, after a primary introduction into the herd one month earlier, without any 
detectable shedding of M. bovis in the colostrum tested.  
In conclusion, M. bovis contamination of colostrum could be evidenced in a small number 
of animals on some recently infected herds. Further research on the minimum infective 
dose is needed, in order to be able to estimate the infection risk from infected colostrum. 
Measures ensuring purchase of negative colostrum are recommended in M. bovis negative 
herds. In positive herds, the within herd transmission due to colostrum is probably low 
compared to the other ways of transmission and may not outweigh the negative effects of 
replacing herd specific colostrum in many herds. 
  




FIGURES AND TABLES 
Table 1. Prevalence of Mycoplasma bovis in freshly calved cattle  
Herd Type (beef, mixed 
or dairy) 
Total number of 
cattle in the herd 
Percentage PCR positive 
colostrum samples 
(positive/number sampled) 
1 Beef 161 0 (0/6) 
2 Beef 139 0 (0/11) 
3 Dairy 74 0 (0/8) 
4 Dairy 103 0 (0/3) 
5 Mixed 209 0 (0/12) 
6 Mixed 121 0 (0/5) 
7 Mixed 216 30.0 (3/10) 
8 Beef 152 10.0 (1/10) 
9 Mixed 205 0 (0/10) 
10 Mixed 245 0 (0/11) 
11 Mixed 316 0 (0/4) 
12 Mixed 433 11.1 (1/9) 
13 Mixed 282 0 (0/11) 
14 Dairy 587 0 (0/63) 
15 Dairy 363 2.8 (2/71) 
16 Dairy 311 0 (0/74) 
17 Beef 241 0 (0/50) 
Table 2. Ct-values of positive samples and their interpretation 
Source herd Ct value Interpretation 
Herd 7 37.14 positive 
Herd 7 38.87 borderline 
Herd 7 38.2 borderline 
Herd 8 38.36 borderline 
Herd 12 29.14 positive 
Herd 15 34.3 positive 
Herd 15 39.8 borderline 
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Mycoplasma bovis is a highly contagious bacterium, which predominantly causes chronic 
pneumonia, otitis and arthritis in calves and mastitis in adult cattle. In humans, 
Mycoplasma species have been associated with post-surgical infections. The present 
study aimed to identify the bacteria associated with three outbreaks of infected seromas 
after caesarian section in Belgian Blue beef cattle. A total of 10 cases occurred in three 
herds which were in close proximity of each other and shared the same veterinary 
practice. M. bovis could be cultured from seroma fluid in five of the six referred animals, 
mostly in pure culture and was isolated from multiple chronic sites of infection (arthritis 
and mastitis) as well. DNA fingerprinting of the isolates targeting two insertion sequence 
elements suggested spread of M. bovis from chronic sites of infection (udder and joints) 
to the postsurgical seromas. Identical genetic profiles were demonstrated in two animals 
from two separate farms, suggesting spread between farms. Mortality rate in the referred 
animals positive for M. bovis in a seroma was 80% (4/5), despite intensive treatment. A 
massive increase in antimicrobial use was observed in every affected farm. These 
observations demonstrate involvement of mycoplasmas in outbreaks of postsurgical 
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Mycoplasma bovis is a worldwide emerging bacterium in cattle (Nicholas, 2011, Spergser 
et al., 2013). This pathogen is highly contagious and a single clone can spread rapidly after 
introduction into a naive herd (Soehnlen et al., 2012, Timsit et al., 2012). M. bovis has 
mainly been associated with chronic unresponsive pneumonia, otitis and (peri)arthritis 
in calves (Maunsell and Donovan, 2009) and with mastitis, arthritis and pneumonia in 
adult dairy cattle (Pfützner and Sachse, 1996). Occasionally M. bovis has been reported to 
cause infections of the tendon sheath (Gagea et al., 2006), keratoconjunctivitis (Alberti et 
al., 2006), meningitis (as a complication of otitis media/interna) (Stipkovits et al., 1993), 
myocarditis (Maunsell and Donovan, 2009), genital infections (vaginitis, abortion and 
vesiculitis) (Pfützner and Sachse, 1996) and decubital abscesses over the brisket and 
joints in calves (Kinde et al., 1993). Especially in chronic stages, the disease is 
characterized by a poor response to antimicrobial agents which compromises animal 
welfare, increases antimicrobial use and causes important economic losses such as weight 
loss, milk drop, loss of carcass quality, increased mortality/culling risk and increased 
veterinary costs (Maunsell et al., 2011).  
Caesarian section (CS) is a common surgical procedure in Belgian Blue (BB) cattle due to 
the muscular hypertrophy of this breed (Michaux and Hanset, 1986). Several pre-, peri- 
and postoperative complications of this surgical procedure have been described (Mijten, 
1998, Kolkman et al., 2010). In BB cattle wound infection and seroma formation occur in 
13% and 1% of CS cases, respectively (Mijten, 1998). A seroma is defined as a sterile fluid 
accumulation between subcutis, muscle layers and/or the peritoneum and is a well-
known complication after surgery, including CS, also in humans (Chelmow et al., 2004). 
Seromas can become infected either through hematogenous spread, surgical wound 
infection or iatrogenic by non-sterile punction (Chelmow et al., 2004). 
In the current manuscript, strain typing based on insertion sequence profiling was used 
to get insights in both intra- and inter-animal spreading of M. bovis in an epidemic of 
infected seromas after CS on multiple farms belonging to a single veterinary practice.     
 
 




MATERIALS AND METHODS 
Animals, examination and sampling  
All study animals were adult BB cows that recently underwent CS, originating from three 
different BB beef herds (farm 1, 2 and 3) of the same veterinary practice. All cows had a 
chronic site of infection (mastitis or arthritis), a non-responsive high fever and lost 
weight. Transabdominal ultrasound was performed with a 7.5 MHz transducer (MyLab 
25 Gold, Esaote Benelux). All animals had seromas intra-abdominally, visualized by 
ultrasound. Aspirations were performed under ultrasonographic guidance, using a 21 G 
needle after local desensitization with procaine 4% (Procainii Chloridum 4% + 
adrenalinum, Kela, Hoogstraten, Belgium) and surgical preparation of the punction site. 
Samples consisted of seroma fluid (aspirations from live animals or swabs from the 
lesions taken at necropsy), joint fluid, milk and swabs of various affected organs post 
mortem. 
 
Figure 1: Fluid accumulation between the greater omentum and peritoneum in a 4 year old cow 
(cow 4) suffering from multiple Mycoplasma bovis infected seromas. 




Microbiological identification   
All samples (Table 1) were stored at 4°C and plated within 24 hours on Columbia agar 
plates supplemented with 5% sheep blood and on a modified pleuropneumonia-like 
organism (PPLO) agar plate (DIFCOTM, BD, NJ) containing  832000 IU/l polymyxin, 0.36 
g/l ampicillin, 23.1% deactivated horse serum and 6.5% yeast extract. Agar plates were 
incubated at 35°C in an atmosphere enriched with 5% CO2. Blood agars and PPLO agars 
were incubated for 48 hours and 7 days, respectively. Bacterial isolates were 













Figure 2: Southern blots of M. bovis isolates from cows with postsurgical seroma formation after 
Insertion Sequence elements typing targeting ISMbov1 and ISMbov2. M1: Seroma  of cow 3, farm 
1, November 2014. M2: Seroma of cow 4, farm 1, April 2015. M3: Udder cow 4, farm 1, April 2015. 
M4: Udder cow 6, farm 3, June 2015. M5: Joint fluid cow 6, farm 3, June 2015. M6: Seroma cow 6, 
farm 3, June 2015. Std: DNA Molecular Weight Marker II, DIG-labeled (Roche) 




Presumptive M. bovis identification was based on the typical fried-egg colony appearance 
on modified PPLO agar and the presence of lipase activity as tested on medium containing 
tween-80 (Devriese and Haesebrouck, 1991).  
Species identification and typing by insertion sequence elements typing 
After mycoplasmal species confirmation by realtime PCR targeting the uvrC gene of filter-
cloned isolates (Rossetti et al., 2010), typing was performed by insertion sequence (IS) 
elements profiling on 6 M. bovis isolates (M1-M6) derived from cow 3 (M1, farm 1), cow 4 
(M2-M3, farm 1) and cow 6 (M4-M6, farm 3). Cow 5 (farm 2) could not be included 
because the sample was analyzed by an external lab without preservation of the sample.  
DNA extractions from axenic cultures of M. bovis were carried out with the peqGOLD 
Bacterial DNA kit (Axonlab, Baden, Switzerland). IS element typing was performed as 
previously described (Thomas et al., 2005; Aebi et al., 2012). Briefly, genomic DNA was 
digested with the EcoRV restriction enzyme and DNA fragments were separated on a 0.7% 
agarose gel and further transferred on positively charged nylon membranes. ISMbov1 and 
ISMbov2 IS elements were further detected using digoxigenin-11-dUTP (dig) labelled 
probes as previously described (Pilo et al., 2003, Aebi et al., 2012). 
RESULTS 
Clinical evolution 
A total of 10 BB cows developed a postsurgical seroma between October 2014 and June 
2015 (6 in farm 1, 1 in farm 2 and 3 in farm 3). Of these animals six were available for 
further examination in this study. The most chronic cases (cow 1 and 2 on farm 1) had 
been treated with penicillin, neomycin, lincomycin, spectinomycin, amoxicillin, florfenicol 
and enrofloxacin at the farm without any improvement.  They both had a very poor body 
condition score (1 on a scale of 5) and were immediately euthanized for welfare reasons. 
Necropsy showed multiple large seromas in the abdomen (Figure 1), abscesses in the 
subcutis, purulent mastitis on four quarters and arthritis in multiple joints in both 
animals. The third cow (cow 3) from farm 1 did not suffer from seromas at admission to 
the clinic, but developed seromas on the left and right side of the abdomen some days 
after first examination. Blood examination showed a low selenium level (51 µg/l, ref: 70-
100 µg/l) and leukocytosis (46.4*109/l, ref.: 6.0-9.0 *109/l). The animal was treated with 




several antibiotics, clinical response followed when treated with gamithromycin 
(Zactran®, Merial®, 6mg/kg intramuscular (IM), every 7 days) and neomycin and 
penicillin (Neopen®, MSD®, 500 mg/100 kg Neomycin, 1.000.000 IU/100 kg penicillin 
IM, daily) for 5 weeks, together with draining and daily rinsing of the seromas with 0.05% 
chlorhexidine. The animal was discharged after 35 days. Treatment was continued at 
home.   
At the farm, the local veterinarian preventively medicated every cow with 2.5 mg/kg 
tulathromycin intramuscularly at the moment of the CS and again 1 week after surgery, 
in an attempt to stop the development of new cases. In April 2015 a new case (cow 4; BB; 
5 years old, 17 days post calving) occurred in the same farm. The animal initially 
presented fever, which did not respond to treatment with neomycin-penicillin, penicillin, 
tulathromycin, tylosin and trimethoprim-sulfonamide. The cow developed arthritis on 
both carpal joints and mastitis with secretion of sandy, granular sediments in all quarters. 
Ultrasonography confirmed the presence of multiple fluid filled structures bilaterally in 
the abdomen. Necropsy showed multiple seromas and general lymphadenopathy. On 
blood examination, serum selenium levels were very low (16 µg/l, ref.: 70-100 µg/l). 
In June 2015 two other farms, belonging to the same veterinary practice, were affected by 
the same condition. Multiple animals were affected, samples were collected from two 
animals (cow 5 from farm 2 and cow 6 from farm 3) (Table 1).  
Bacteriology and typing of isolates 
An overview of the samples taken from the 6 cows with post-surgical seroma formation 
from the three farms and bacteriological culture results are presented in Table 1. M. bovis 
was isolated in pure culture from the post-surgical seromas in 4 out of 5 cases sampled 
and in one case together with Trueperella pyogenes. No seroma fluid was collected from 
cow 2. In several animals M. bovis was also cultured from the udder and/or joints (Table 
1). 
IS elements typing showed a single M. bovis profile in animals from herds 1 and 3 (cows 4 
and 6, respectively) (Figure 2). In herd 1 the isolates from cow 3 (November) and cow 4 
(April) were very similar, especially when using ISMbov1 IS elements, but not identical. A 




single IS element profile was observed in the udder and seroma fluid of cow 4 and in the 
udder, joint and seroma fluid from cow 6 (Figure 2). 
 
  
Table 1. Bacterial culture results from different sampling sites of 6 beef cows with post-surgical 
seroma formation. 
 Cow 1 Cow 2 Cow 3 Cow 4 Cow 5 Cow 6 
Sampling site       
Joints T. pyogenes and 
M. bovis 
M. bovis N/A N/A N/A T. pyogenes 
and M. bovis 
Udder T. pyogenes and 
M. bovis 
M. bovis M. bovis M. bovis N/A T. pyogenes 
and M. bovis 
Kidney N/A Negative N/A N/A N/A N/A 
Lung Negative N/A N/A N/A N/A Negative 




N/A M. bovis M. bovis M. bovis T. pyogenes 
and M. bovis 
M. bovis: Mycoplasma bovis; T. pyogenes: Trueperella pyogenes; A. fumigatus: Aspergillus 
fumigatus, N/A: not available 
Cow 1-4: Farm 1, Cow 5: Farm 2, Cow 6: Farm 3.  
 
 





In human medicine, wound infection caused by Mycoplasma hominis is a reported 
complication of CS (Phillips et al., 1987, Maccato et al., 1990). In the present study, M. bovis 
was isolated from seromas following CS in five cows from three different farms. To the 
author’s knowledge the involvement of Mycoplasma spp. in wound infections or seromas 
in animals has not been previously reported. Possibly the importance of M. bovis and other 
Mycoplasma spp. is underestimated, since the selective growth media required for their 
isolation are rarely used in routine bacteriological examinations of wound infections and 
Mycoplasma spp. either don’t grow or are easily overgrown on regular blood agar plates. 
In the present outbreaks, M. bovis infections resulted in a severe clinical presentation with 
a very poor outcome. A single animal could be saved after a long hospitalization period. 
The lack of clinical break point values for M. bovis made the selection of an effective 
antibiotic difficult, resulting in the use of different molecules. However, given the chronic 
state of disease at the time of submission, little efficacy of antimicrobial therapy is to be 
suspected and euthanasia is strongly advised for both economic and welfare reasons. Next 
to the loss of the animals, the condition resulted in a massive increase in antimicrobial use 
in the affected farms, partly due to therapy failure and partly because of the fear of the 
development for new cases. Despite the apparent improvement of the situation after 
preventive antimicrobial use, the authors wish to underscore that no evidence to support 
this measure is provided. In contrast, such prophylactic treatments might further increase 
antimicrobial selection pressure, selecting for multi-drug-resistant bacteria, including M. 
bovis isolates as recently reported in France (Gautier-Bouchardon et al., 2014).  
M. bovis is known to spread hematogenously from the lungs to the joints (Maunsell and 
Donovan, 2009). The current case series strongly suggest hematogenous spread of M. 
bovis to the surgical incision site from a primary site of (chronic) infection, most probably 
the udder and joints. The presence of identical isolates in different body sites of the same 
animal also points in this direction. It is not clear why this spread to the seroma occurred: 
both virulence factors related to the strain or physiological immune suppression due to 
parturition might have played a role.  
Possibly, impaired immunity following parturition facilitated dissemination of M. bovis. 
Also the low selenium levels of cow 3 and 4 might have played an additional role in the 




illness, as this deficiency has been linked to a lowered periparturient immunity level 
(Sordillo, 2013). 
A most interesting observation was the presence of an identical isolate in two different 
farms, suggesting the spread from one farm to the other. Direct spread through animal 
contacts is not likely since there were no connecting pastures or animal transports 
between the farms. Airborne transmission of M. bovis from one herd to another cannot be 
excluded, but has not yet been demonstrated in cattle (Soehnlen et al., 2012). Therefore, 
indirect spread through materials or persons, visiting both farms, is the most probable 
route of transmission.  
In conclusion, this report adds infection of post-surgical seromas to the list of M. bovis 
associated pathology. The condition can affect multiple cows in a short period and has a 
poor prognosis. Early detection by farmers and practitioners of animals with chronic sites 
of M. bovis infection and subsequent culling is likely to be the best option to prevent or 
contain this pathology. Appropriate biosecurity precautions should be taken by all farm 
visitors including attending veterinarians to prevent transmission among herds. 
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Mycoplasma bovis is a pathogen which is seen as one of the rising threats in modern-day 
cattle farming. Its capacity to hide in apparently healthy animals, combined with its highly 
infective nature makes it hard to stop its spread once present. As such, the aim of this 
thesis was to map the presence of this bacterium in Belgian herds, and fill in gaps in the 
epidemiological knowledge of M. bovis, to be able to give the best possible and 
scientifically underbuilt advice on prevention and control. The most important 
conclusions from this thesis and their practical implications are discussed below.  
PREVALENCE OF MYCOPLASMA BOVIS IN BELGIUM (CHAPTER 3) 
In a study performed in 2009, 1.5% of all Belgian dairy herds tested positive for M. bovis 
on BTM culture (Passchyn et al., 2012). However, field reports and laboratory analysis in 
recent years seemed to indicate a rise in M. bovis prevalence and subsequent disease in 
Belgian herds (Unpublished data, DGZ). The development of ELISA and PCR tests for use 
on BTM samples provided a quick and easy-to use alternative to bacterial culture for herd-
screening purposes (Nielsen et al., 2015; Petersen et al., 2016). We used these novel tools 
to determine the prevalence of M. bovis in Belgium, and found it a lot higher than expected. 
Where repeated culture, which is somewhat comparable to PCR in sensitivity (Gonzalez 
and Wilson, 2003), only resulted in a 1.5% prevalence (Passchyn et al., 2012), PCR on BTM 
in this study resulted in 7% of all farms testing positive. Since M. bovis excretion is 
intermittent, this amount of infected farms is possibly even an underestimation: if 
shedder cows are separated from the milking herd or are dry at the time of testing their 
milk would, as such, also not be included in the BTM (Gonzalez and Wilson, 2003). The 
results become even more interesting when looking at the antibody ELISA tests 
performed on the same samples as the PCR. A true prevalence of 24.8% was found, 
indicating that one out of four farms in Belgium had contact with M. bovis in previous 
months. This number goes above 30% when PCR results are included, as there was no 
overlap between PCR and antibody ELISA positive farms in this study.  
Several explanations are possible for this non-overlap between the two tests. As shedders 
can excrete M. bovis intermittently, it is possible that part of the persistently infected 
animals were not shedding at that moment. Animals with clinical mastitis might have been 
separated from the milking herd as well, resulting in a negative BTM sample on PCR while 
other animals could still contribute to the antibody level. One could argue that the 
presence of M. bovis could cause the antibodies present in the BTM sample to bind to the 




bacteria, instead of to the antigen provided by the ELISA. This could be the explanation 
why, in a study by Parker et al. (2017), no overlap could be seen between PCR and ELISA 
analysis on BTM either. Another possible explanation to this discrepancy is that 
antibodies as measured on BTM in the aforementioned previous study by Parker et al. 
(2017) dropped below the detection limit at 8-12 months after the first M. bovis 
introduction, whilst M. bovis could still be detected by PCR occasionally. One more 
possibility is that PCR will be positive faster compared to antibody ELISA, and might 
already test negative again by the time the ELISA tests positive. Recent findings also 
showed that the commonly used BIO-X K302 has a far lower sensitivity compared to a 
MilA ELISA, possibly also influencing results (Petersen et al.,2018b).  
In any way, the prevalence of M. bovis DNA in BTM seems a lot higher in Belgium 
compared to other recent studies from Denmark, the Netherlands and Southern France 
(See figure 9 p 27) (Arcangioli et al., 2011; Nielsen et al., 2015; Hogenkamp, 2017). A 
possible explanation on this discrepancy might be the high density of cattle farms in 
Belgium and the high level of trade going on between these farms (Ensoy et al., 2014). 
However, the same high density and complex contact structure is present in the 
Netherlands, and a recent study only found a BTM prevalence of 1% in this country (van 
Klink and Koorevaar, 1999; Hogenkamp, 2017). In conclusion, the combination of both Ab 
ELISA and PCR tests on BTM will result in a higher accuracy and is therefore 
recommended. 
The seroprevalence of M. bovis was also determined in Belgian beef herds on samples 
from the 2014 Belgian winter screening for regulated diseases (Gille et al, unpublished 
results). In 100 at random selected herds, five serological samples were conveniently 
taken. Herds were considered positive when at least one sample was positive. The 
between herd prevalence was 21%, with the within herd prevalence ranging from 20 to 
60% (Gille et al, unpublished results). The seroprevalence of M. bovis in Europe shows a 
high variety between countries, ranging from almost nonexistent in the Nordic countries 
to 100% in Hungary (See figure 9 p 27). Comparison between serology and BTM ELISA 
results is difficult at this time, as serological research has shown an underdiagnosis of 
cases if only milk is analyzed, since antibodies will only appear in the presence of M. bovis 
mastitis (Petersen et al., 2018a). As such we are unable to say which sector is most 
affected by M. bovis in Belgium at this time. Both beef and dairy herds are still far less 




affected compared to the veal industry, where previous work resulted in isolation and 
seropositivity in almost every herd (Pardon et al., 2011; Pardon, 2012). 
In conclusion, the high prevalence of M. bovis in both beef and dairy herds in Belgium in 
recent years underscores the need for herds currently negative to guard their biosecurity. 
Testing animals at the time of purchase is crucial. The use of PCR and Ab ELISA in parallel 
testing on BTM from a prospective herd before purchasing cattle from said herd could 
mean an improved security to make sure M. bovis is not introduced as well. When 
purchasing non lactating animals or purchasing from a non-dairy herd, serological or 
swab sampling of the animals and/or a randomized sampling of some animals of the herd 
is advised. It is unclear whether an animal testing positive on serology is a carrier, and 
some clinically ill animals might not have detectable antibodies either, but if one or more 
animals or the BTM test positive, and the prospective herd is negative, no animals should 
be purchased to avoid the introduction of M. bovis in the herd.  
RISK FACTORS FOR THE PRESENCE OF M. BOVIS IN A HERD  
In the second part of the first study of this doctoral thesis (Chapter 3), risk factors for a 
herd testing M. bovis positive on BTM were investigated. Previous studies identified 
purchase as the main risk factor for M. bovis presence on herd level, which seems logical 
since this is one of the main pathways of introduction into a herd (Gonzalez et al., 1992; 
Maunsell et al., 2011). However, even though purchase in the year before the positive test 
was found to be a possible factor on univariable analysis in our study, this factor was 
linked to the presence of a breeding bull, and of these two the breeding bull was more 
significant after stepwise backward elimination. This could imply that the role of the bull 
in M. bovis’ epidemiology might have been underestimated in the past. In previous studies, 
the bull might not have been taken into account when building the risk factor analysis 
model. The use of a teaser bull could not be taken into consideration due to the low 
amount of farms that used one in this study. 
The possible importance of the presence of a bull ties in with the recent findings of 
Haapala et al. (2018), demonstrating the use of AI semen from infected bulls as the cause 
of M. bovis introduction into previously seronegative herds in Finland. Since farmers grow 
more and more conscious of biosecurity and closed herds become more common, 
focusing only on the purchase of live animals as a possible source is likely insufficient. 
More focus should be placed on other possible ways of M. bovis introduction. This is 




illustrated by the recent introduction of M. bovis into New Zealand (NZ), a country which 
had not imported any cattle in the last five years before detection and only 110 animals 
in total in the 5 years before (Ministry for Primary Industries, 2017). In this instance as 
well, AI was looked at as a possible source, but it was not the only suggested way of 
introduction. In the last 10 years, an average of around 240000 straws of bovine semen 
and 565 bovine embryos were imported into NZ every year (Ministry for Primary 
Industries, 2017). The antimicrobials used as a means of decontamination of AI semen 
were reported as possibly ineffective for the complete inactivation of M. bovis (Bielanski 
et al., 1989; Visser et al., 1999; Ministry for Primary Industries, 2017). Next to this, other 
fomites such as imported feed and farm equipment and the import of other ruminant 
species were considered as well. In this thesis (chapter 5) we illustrated that the 
veterinarian can act as a possible passive transmitter of the bacteria as well. This was also 
described by Gonzalez et al. (1992), who saw all herd visitors in contact with manure and 
bodily secretions of cattle as a transmission risk.  
Next to the identification of the bull as a risk factor, the presence of a separate calving pen 
was found to be a protective factor. A distinction between a single- or group calving pen 
could not be made due to a lack of power. The protective effect of the calving pen might 
be linked to another part of M. bovis’ epidemiology often disregarded in the past, which is 
the presence of M. bovis in vaginal secretions, especially at calving and during abortion 
(Stalheim and Proctor, 1976; Bocklisch et al., 1986). It is possible that the protective effect 
stems from the separation of the (stressed) calving animal from the herd. Stress and 
cortisol were shown to exacerbate disease and induce shedding in infected animals 
(Caswell and Archambault, 2008; Alabdullah et al., 2017; Alabdullah et al., 2018). 
Furthermore, the periparturient period in itself gives cause for immunosuppression, 
possibly giving M. bovis another chance to start shedding or cause disease (Sordillo, 2013). 
When separating the animal around parturition, this will shield the other cattle from a 
possible high load of M. bovis shed during the parturition, either through vaginal 
secretions or nasal secretions. Furthermore, this might protect the cow herself in the 
period where she will be most vulnerable immunity wise, possibly avoiding an infection 
of cows who will be at the peak of their lactation soon and as such production wise will 
be a bigger contributor to the BTM. In any case, the definite reason of the protective effect 
of the calving pen is unclear at this time. As such, further research on the presence of M. 
bovis around calving (and survival in the environment) is necessary, especially since the 




colostrum study in chapter 4.2 seems to suggest that there is little indication of 
periparturient rise of M. bovis, as only a few colostrum samples contained M. bovis DNA.  
Interestingly, both the bull and the absence of a calving pen were identified as risk factors 
in an article by Kemmerling et al. (2009) on the prevalence and risk factors of Chlamydia 
sp. in cattle herds. Ruminant Chlamydia species such as Chlamydia abortus and Chlamydia 
pecorum can also be the cause of pneumonia, arthritis, conjunctivitis and reproductive 
problems and generally get transmitted via veneral or feco-oral routes (Kemmerling et 
al., 2009). Kemmerling hypothesized that the relative risk of transmission using AI was 
limited to those animals for which semen of a certain bull is used, whereas if only one bull 
is used on a farm, all bred animals are at risk. The same reasoning can probably be used 
in the relative risk of M. bovis semen as well. An added difficulty in the role of the bull as 
transmitter is that, even when the bull tests negative at purchase, they can get infected 
when used for breeding in a seropositive herd, without any clinical signs of being infected. 
Afterwards, this animal could possibly infect a large amount of cows while escaping 
detection as this is generally done through e.g. milk testing (Hazelton et al., 2018a). 
On univariable analysis, next to purchase, the use of a breeding bull and the absence of a 
calving pen, several other factors were identified which could warrant further 
investigation. In regard to youngstock raising, individual housing of young calves seemed 
to be protective, but this factor was removed due to too few farms not using this 
management system (2/2 farms not using individual housing tested positive on BTM). 
The use of a high-pressure cleaner to clean calf pens between occupation seemed to be a 
protective factor as well. Since direct contact is an important way of transmitting M. bovis 
in young calves and contact with fomites had been implicated in the past, these risk factors 
seem logical. However, other prospective risk factors were less logical. The self-reported 
presence of otitis in a farm was not predictive for having M. bovis. In fact, all farms (5/5) 
reporting to have otitis (interpreted by the presence of head tilt) in youngstock did not 
test positive on BTM. A possible explanation for this matter could be that the BTM testing 
positive is in no way linked to circulation of M. bovis in youngstock, and could be tied to 
strain dependent disease presentations (mastitis vs otitis in calves) or another disease 
causing otitis (such as H. somni) being present. Tubed feeding of colostrum was also a 
rather unexplainable risk factor for M. bovis. In this case, it is possible that this is caused 
by a confounder: the knowing that M. bovis is present could have led farmers to take 




control measures on the farm, one of which is ensuring a good immunity transfer. 
Furthermore, this factor also had relatively little responses on one side, which can have 
influenced results. 
In conclusion, the importance of semen and genital secretions in the transmission of M. 
bovis should be reevaluated. Although AI semen has been the cause of introduction in 
herds before, the amount of animals affected inside a herd is possibly lower compared to 
the use of a breeding bull. However, the global impact of infected AI semen could be 
higher, especially if the carrier animal is in high demand. Surveys in AI centers should be 
considered to map the spread and impact of the bacteria in these facilities, but the choice 
of technique should be evaluated as well. Recent research by Vähänikkilä et al. (2018) has 
shown that real time PCR is an excellent method to detect M. bovis in semen samples, but 
as this method only detects M. bovis DNA, no distinction can be made between live and 
killed M. bovis. Furthermore, the M. bovis concentration in semen and the infective dose 
are both still unclear. Next to this, the presence of M. bovis in vaginal secretions and 
amniotic fluid and the possible transmission risk should be investigated as well. One 
recent study by Hazelton et al. (2018b) found that 18.8% of all cows having a clinical M. 
bovis mastitis were also shedding M. bovis vaginally. In Flanders, in 2015, in more than 66 
% of the investigated abortion cases (n=5293) no cause could be found on aerobic culture 
(DGZ, unpublished results). Since M. bovis was shown to cause abortions in experimental 
and clinical settings, investigations into the role of M. bovis in abortion cases in 
seropositive herds might be interesting as well (Watson et al., 2012). 
MYCOPLASMA BOVIS AND COLOSTRUM  
In chapter four of this thesis, we zoomed in on colostrum as a possible source of M. bovis 
infection for neonatal calves. The assumption of its infective nature has been made 
previously, but no scientific evidence of M. bovis even being present in colostrum was 
provided until now (Godden et al., 2006). As colostrum uptake is an essential part of the 
immunity in newborn calves, withholding colostrum as a preventive measure will have a 
large impact on the newborn calf. In farms, the colostrum surplus is often frozen to act as 
a reserve at a later time if for example another dam does not produce enough colostrum 
or the colostrum has a low quality. Trade of frozen colostrum between farms is common 
in Belgium as well, especially from dairy farms, which often have a surplus (DGZ, 2014). 




Decontamination of colostrum by use of batch pasteurization or gamma irradiation is 
possible but costly and hard-to implement in smaller farms. Pasteurization of colostrum 
is a very temperature sensitive process, as the immunoglobulins present will denature 
when heated, possibly resulting in a too low immunoglobulin content post pasteurization 
if performed incorrectly (Godden et al., 2003; Godden et al., 2006; McMartin et al., 2006). 
Even when performed correctly, a drop in immunoglobulin content is visible, however, 
when calves are given enough colostrum (4L) in the critical window, no difference is 
visible between non-pasteurized and pasteurized colostrum feeding (Godden et al., 2003). 
Recently, small-batch pasteurizers have come on the market as well, enabling farmers to 
pasteurize two to four liters of colostrum at a time, freezing it and feeding it to the next 
calf born on the farm. In the first part of this section (chapter 4.1), the effect of freezing 
colostrum on the survival of a known concentration of M. bovis was tested. A single freeze-
thaw cycle resulted in a one log drop of the M. bovis CFU/ml. A second freeze-thaw cycle 
resulted in another 0.5 log drop. These findings have shown that freezing is probably not 
a valid control measure in the decontamination of colostrum from M. bovis and that 
freezing of colostrum samples does not make it unusable for further epidemiological 
studies or monitoring programs on M. bovis through bacteriological culture.  
In the second part of this section (Chapter 4.2) the actual presence of M. bovis DNA in 
colostrum was assessed, by use of a realtime PCR. Of a total of 370 samples, only seven 
samples tested positive for M. bovis DNA. Next to the cross-sectional data gathered on 
thirteen farms, four farms were followed up over a longer time period, in the hope of 
identifying risk factors for having a positive colostrum sample. Unfortunately, due to the 
low amount of positive samples, no risk factor analysis could be performed.  
However, since M. bovis circulation was confirmed on all farms throughout the study and 
very little colostrum samples tested positive, the importance of colostrum as a carrier for 
M. bovis might be relatively low compared to other agents, especially when colostrum is 
fed on a 1-on-1 basis. However, since only one farm was confirmed to be in the acute phase 
of a M. bovis outbreak, conclusions need to be interpreted carefully, as significant 
shedding in the acute period of infection cannot be excluded completely.  Of course, PCR 
is only capable of detecting DNA, not the live bacteria, and therefore further research on 
this substrate is necessary. Furthermore, the PCR tests used for the assessment of the 
presence of M. bovis DNA in colostrum were not developed for this substrate, possibly 




reducing the sensitivity. Interaction of the test with other Mycoplasmataceae is always a 
possibility as well. 
Notwithstanding these limitations, the conclusion of this chapter is that, in herds where 
M. bovis circulation is confirmed, colostrum probably carries a relatively low risk of 
infection compared to other routes. In these herds, focus should lay on the prevention of 
infection of young stock through more common ways, such as direct contact and the 
ingestion of infected milk. Pooling of colostrum needs to be avoided. Treatment of 
colostrum through pasteurization can be done at 60°C for 30 minutes, but care should be 
taken not to overheat the colostrum (Godden et al, 2003). Other treatment methods such 
as acidification of colostrum to a pH of 4, which has been used before on M. bovis infected 
milk, with a successful destruction of all M. bovis present after 1 hour, might be 
investigated in the future (Parker et al., 2016). In herds without a known M. bovis 
presence, purchase of untreated colostrum from other farms should be avoided at all cost 
to negate the transmission risk.  
An interesting juxtaposition in the findings of this thesis is the seeming absence of a 
periparturient rise for M. bovis in colostrum in chapter 4.2, which contrast the findings in 
chapter 3 that indicate that calving cattle could possibly pose a risk for M. bovis circulation 
on the farm, and the findings in chapter 5 that showed that several of the animals affected 
by M. bovis seromas also had a very low selenium level, which can cause a lowered 
immunity and a higher risk for infection. A possible explanation of this juxtaposition is the 
fact that in endemic herds only a relatively low percentage of animals will be carrier of M. 
bovis (Timonen et al., 2017), and therefore only a few animals might be experiencing a 
periparturient rise and shed M. bovis in colostrum. Further research on shedding in 
colostrum on recently infected herds with the use of different techniques, and research of 
the importance of M. bovis shedding in vaginal and periparturient excretions will 
hopefully aid in providing an explanation of this juxtaposition. 
  




MYCOPLASMA BOVIS AND SEROMAS 
In chapter 5, a case series is described of a cluster of postsurgical seromas in beef cattle 
(Belgian blue) after CS, in combination with high fever and typical M. bovis associated 
diseases such as mastitis and arthritis. Through culture M. bovis could be isolated out of 
10 cases. After subsequent strain typing, the strain pattern found on two separate farms 
indicated a spread from one farm to the other. As mentioned above, the veterinarian was 
seen as a possible link between farms, a feat also described for other bacteria, such as 
Actinobacillus lignieresii (De Kruif et al., 1992; Rossi et al., 2017). In the described case 
series, one animal was saved after months of treatment. However, the economic relevance 
and impact on animal welfare of this treatment was questionable as was the resulting high 
level of antimicrobial use.  
Through IS strain typing, the same strain was shown to be present in the seroma, the 
joints and in milk and udder samples. As such, it was suspected that M. bovis spread 
hematogenous from a primary site of infection to the surgical site. However, this did not 
explain fluid accumulations of the same nature as the surgical (left sided) seromas on the 
right side of the abdomen, which were found in some of the affected animals. 
Furthermore, several animals in this study suffered from a very low selenium level, which 
could have been a predisposing factor in the severity of the M. bovis disease symptoms. 
Selenium deficiency is a frequent finding in Belgian herds, especially in Belgian Blue beef 
herds, and can lead to several pathologies, one of which is a suppression of the immunity 
of the affected animal (Guyot et al., 2009; Mehdi and Dufrasne, 2016). 
In the discussion of the paper it was stated that this was the first paper to describe 
Mycoplasma sp. wound infections or seromas in animals. However, a few papers on wound 
infections have been published before (Ayling et al., 2011) 
In response to this paper, the impression of field veterinarians in Belgium was that all 
postsurgical seromas were caused by M. bovis. However, the authors wish to underscore 
that this was not the conclusion of the above article. In the above article, M. bovis was 
present, and probably did cause seromas in the affected cattle. However, all investigated 
animals had other lesions where M. bovis was isolated out of as well, which could have 
been the primary infection site from which the bacteria spread to the operation wound. 
Subsequent research performed by Evrard et al. (2017) showed that only in a minor 
subset (4.1%) of all examined seroma cases, M. bovis could be isolated from the seroma 




fluid. Nonetheless, when a seroma (typically diagnosed with ultrasound after the typical 
symptoms of weight loss and a high fever resistant to therapy appear after CS) is 
diagnosed together with other M. bovis associated diseases such as mastitis or arthritis, 
care should be taken to avoid the infection of other animals on the farm, especially when 
the choice is made to try to treat it. Generally, the seromas need to be opened and the 
seroma fluid drained, which could pose a large infection risk for the rest of the herd, 
especially since this is often done in the same (often the only) restraining box used for CS, 
and the seromas can be very large, sometimes containing more than 40 liters of fluid 
which will splash up when drained. 
 
  





The identification of possible new transmission routes (by epidemiological studies, strain 
typing, infection tests or otherwise) is a good start to develop more effective prevention 
and control measures. It is important to realize that the infective capacity of the genital 
pathway, seroma fluid and colostrum still need to be evaluated further, as well as other 
possible infection routes such as the environment or other animal species. Vaccination 
might be a way to stop further spread, but uninfected herds especially need easy to use 
rapid and reliable methods of screening purchased cattle to reduce the risk of introducing 
the bacteria. A more reliable method of diagnosing persistently infected shedders and 
advice on how to deal with the disease once introduced is necessary as well. Strain 
analysis should be done to find out whether M. bovis has strain dependent disease 
expressions (eg. pneumonia; mastitis; otitis;…) as suggested before. 
Antimicrobial resistance is a huge problem in human and animal medicine. M. bovis is an 
important driver of (repeated) and unsuccessful antimicrobial use, resulting in a major 
selection pressure for many other bacterial species. Rapid detection of M. bovis is 
necessary to adapt treatment and prevent the unnecessary use of antimicrobials M. bovis 
is naturally resistant to. Next to fast diagnosis, clinical breakpoints to define antimicrobial 
susceptibility are urgently needed as well to limit therapy failure and useless 
antimicrobial use. As such, the availability of a fast, reproducible method for the 
determination of MIC values is also essential.  
The author would recommend (inter)national monitoring of M. bovis prevalence and the 
introduction of farm certifications in European herds to contain further spread. Possibly 
the information provided in this thesis will help to convince farmers, veterinarians and 
governmental organizations of the importance of M. bovis and the need of a combined 
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In the last decade, Mycoplasma bovis has evolved to an economically important cause of 
disease, reduced welfare and antimicrobial use in cattle worldwide. Most commonly 
known as a cause of mastitis, pneumonia and arthritis, M. bovis has been associated with 
several other clinical manifestations as well. Due to its innate resistance to antimicrobials 
targeting the cell wall and chronicity linked to several virulence factors such as the 
immune evasion by Vsps, its capability to produce a biofilm and its ability to hide 
intracellularly, treatment is often disappointing. In recent years, a decreasing 
susceptibility to other antimicrobial agents has been reported, with country specific 
differences.  
To date both effective treatment and vaccines are not available. As such, development of 
prevention and control measures based on identification of risk factors for M. bovis spread 
and disease is seen as the most important way to tackle problems caused by this 
bacterium. The development of prevention programs aiming to stop the introduction of 
M. bovis onto novel farms, and control programs interrupting the transmission within an 
already infected farm depends on knowledge of these risk factors and possible infection 
routes. Where the main transmission routes such as direct contact, milking and the 
consumption of infected milk are well known, others have been less explored. As such, the 
general aim of this thesis was to identify previously underestimated infection sources, 
disease presentations and risk factors, and give an update on the prevalence of M. bovis in 
Belgium.  
In the first study of this thesis (Chapter 3), the prevalence of M. bovis in Belgian dairy 
herds was determined by antibody ELISA and PCR analysis of bulk tank milk (BTM). Of all 
farms, 7.1 % had detectable presence of M. bovis DNA in the BTM. On antibody ELISA, the 
true prevalence was 24.9%. Interestingly, there was no overlap of ELISA and PCR positive 
herds, leading to a total prevalence of 32% of all Belgian herds being in recent contact 
with M. bovis. This is worrisomely high compared to a previous culture based study in 
Flanders and to the prevalence levels in neighboring countries. The potential economic 
damage of this risen prevalence is high, given M. bovis’ role in cattle disease and 
antimicrobial use. 
Furthermore, in this study two new risk factors for the presence of M. bovis in BTM were 
found: the presence of a breeding bull on the farm and the absence of a calving pen. The 





farms 4.7 times higher odds for having a positive BTM sample. Farms who did not use a 
calving pen to separate cows at the time of calving had 3.7 times higher odds of testing 
positive. The identification of these risk factors together with the recent identification of 
AI as a source of infection might mean the start of more specific searches on the infective 
capacity of M. bovis in the genital tract. 
Colostrum is often considered a possible source of M. bovis infection. In Chapter 4 the 
presence of M. bovis in colostrum was assessed through two separate studies. In the first 
study (Chapter 4.1), the survival of M. bovis in colostrum through freeze thaw cycles was 
assessed under different thawing conditions. Freezing and subsequent thawing was 
shown to reduce the amount of CFU with 1 log after a single cycle, and with 1.5 log after 
two cycles, with no added effect from the thawing temperature. As such, freezing is 
probably not a hurdle for epidemiological research where colostrum needs to be frozen 
before analysis, but relevance as a preventive measure is unclear as long as the minimum 
infective dose is not known.  
In Chapter 4.2, the presence of M. bovis in colostrum was assessed by PCR analysis on 368 
samples taken on 17 farms. Of these, only 7 samples tested positive, which corresponds 
with a prevalence of 1.9%. As such, the general assumption that colostrum is a highly 
infected substance seems to be grossly overstated, and the current control measure of 
withholding colostrum on already positive farms to prevent spread to neonatal calves 
might need to be reconsidered. Likely, individual housing combined with the feeding of 
pasteurized milk or milk replacer is a more effective control in infected herds. However, 
for M. bovis negative herds, purchase of non-decontaminated colostrum should be seen as 
an infection risk.  
The next chapter (Chapter 5) describes the isolation of M. bovis out of seromas, a novel 
predilection site especially important in Belgium because of the high number of caesarean 
sections performed in the Belgian Blue breed. Ten animals were shown to be affected by 
postsurgical seromas infected with M. bovis. IS typing revealed that the strain isolated 
from the seromas and other M. bovis predilection sites such as the joints and the udder 
was the same, which could indicate a spread from this primary infection site to the 
seroma. Through strain typing, spread of the same strain between two farms was shown, 
possibly linked to the veterinarian.  




In conclusion, M. bovis is present in a significant number of Belgian herds. Even though 
purchase of carrier animals is the main cause of introduction of M. bovis into new herds, 
the identification of the bull as a risk factor for a positive BTM and the possible spread of 
the seroma-inducing M. bovis strain by the veterinarian should urge us to investigate 
other possible causes of transmission as well. Colostrum seems to be of relatively low 
importance in the transmission in a herd compared to other factors, given the low PCR 
prevalence, but M. bovis DNA can be present. The results of this thesis also point toward 
the possible importance of both the bull and the exposure of cattle to M. bovis at the time 
of calving (through uterine secretions or immunosuppression) for the within-herd 
transmission of M. bovis. 
These additions to the epidemiology of M. bovis might aid veterinarians and farmers to 
develop more effective prevention and control programs in the near future to tackle the 
spread of this devastating bacterium. 














Mycoplasma bovis is in het laatste decennium wereldwijd uitgegroeid tot een economisch 
belangrijke oorzaak van ziekte, verminderd welzijn en antibioticagebruik bij runderen. 
Meest berucht als veroorzaker van mastitis, pneumonie en artritis, heeft M. bovis 
daarnaast ook nog verschillende andere ziektebeelden. Behandeling is vaak zeer 
teleurstellend door de natuurlijke resistentie van de kiem tegenover antibiotica die de 
celwand als doel hebben en het vaak chronische ziektebeeld gelinkt aan verschillende 
virulentiefactoren.  
Op dit moment zijn noch een bevredigende behandeling noch efficiënte vaccins 
voorhanden. De ontwikkeling van preventie- en controlemaatregelen op basis van de 
identificatie van risicofactoren voor de verspreiding van- en het veroorzaken van ziekte 
door M. bovis wordt beschouwd als de belangrijkste maatregel. Preventieprogramma’s die 
de introductie van M. bovis op nieuwe bedrijven willen stoppen en controleprogramma’s 
die de transmissie van M. bovis in reeds besmette bedrijven willen inperken hebben nood 
aan deze risicofactoren en identificatie van mogelijke introductieroutes om gepaste 
richtlijnen te kunnen opstellen. De belangrijkste transmissieroutes, zijn direct contact, het 
melkproces en de consumptie van geïnfecteerde melk. Andere routes zijn veel minder 
onderzocht. Het hoofddoel van deze thesis was dan ook kennis toe te voegen aan de reeds 
bestaande epidemiologische kennis van M. bovis, ter bevordering van de ontwikkeling van 
betere controle en preventie. 
In de eerste studie van deze thesis (Hoofdstuk 3) werd de prevalentie van M. bovis op 
Belgische melkveebedrijven bepaald met behulp van PCR en ELISA analyse op tank melk 
(TM). Wanneer PCR gebruikt werd testte 7.1% van alle bedrijven positief op TM. Met 
ELISA werd de ware prevalentie vastgelegd op 24.9%. Er was geen overlap tussen de PCR 
en ELISA positieve bedrijven, wat maakt dat 32% van de Belgische bedrijven in contact 
was met M. bovis op het moment van het onderzoek. Dit gehalte lijkt onrustwekkend hoog 
in vergelijking met de in 2009 bepaalde prevalentie van 1.5% op cultuur., en ligt ook hoger 
dan deze bepaald in buurlanden. Deze stijging is -gezien de economische impact van M. 
bovis en zijn rol in verschillende ziektevormen en antibioticagebruik- slecht nieuws. 
Verder werden er in deze studie twee nieuwe risicofactoren geïdentificeerd voor de 
aanwezigheid van M. bovis in de kudde: de aanwezigheid van een dekstier, en de 
afwezigheid van een afkalfstal. Wanneer een stier gebruikt werd (eventueel naast 





TM staal. Bedrijven die geen afkalfstal gebruikten (zonder onderscheid of er individueel 
gestald werd of niet) hadden 3.7 maal hogere odds op het positief testen van de TM. De 
identificatie van deze risicofactoren naast de recente identificatie van kunstmatige 
inseminatie als infectiebron wijst op het nut van meer specifiek onderzoek naar de 
infectieuze capaciteit van M. bovis in het genitale apparaat. 
Colostrum is veelvuldig vermeld als een mogelijke bron van M. bovis, echter zonder 
onderbouwing. In hoofdstuk 4 werd de mogelijke rol van colostrum onderzocht met 
behulp van twee verschillende studies. In de eerste studie (Hoofdstuk 4.1.) werd het 
overleven van M. bovis in colostrum doorheen verschillende vriesdooicycli geëvalueerd. 
Het vriezen en vervolgens ontdooien resulteerde in een daling van de hoeveelheid kolonie 
vormende eenheden met 1 log na een enkele cyclus, en met 1.5 log na twee vriesdooicycli, 
zonder dat er een invloed van de dooitemperatuur kon vastgesteld worden. Vriezen is 
aldus volgens dit onderzoek geen belemmering voor epidemiologisch onderzoek waarbij 
colostrum bevroren dient te worden voor analyse, maar de verdere relevantie als een 
mogelijke preventieve maatregel is nog onduidelijk.  
In Hoofdstuk 4.2. werd de aanwezigheid van M. bovis DNA in colostrum onderzocht door 
gebruik van PCR op 368 stalen afkomstig van 17 bedrijven. Van deze stalen gaven slechts 
7 stalen een positief signaal, corresponderend met een prevalentie van 1.9%. De algemene 
aanname dat colostrum een hoge graad van infectie heeft lijkt dus op basis van onze studie 
een overschatting. De huidige preventiemaatregelen waarbij geadviseerd wordt 
colostrum te weerhouden op reeds besmette bedrijven om de spreiding naar neonatale 
dieren te vermijden moeten dan ook heroverwogen worden ten voordele van andere 
maatregelen zoals individuele opfok. Voor M. bovis negatieve bedrijven echter is de 
aankoop van niet steriele biest contra-geïndiceerd en moet dit worden beschouwd als een 
infectierisico.  
Het volgende hoofdstuk (Hoofdstuk 5) beschrijft de isolatie van M. bovis uit seromas, een 
nieuwe predilectieplaats die voornamelijk in België van belang is. De aanwezigheid van 
een groot aantal dieren van het Belgisch Wit-Blauwe ras maakt dat de hoeveelheid 
keizersneden (en bijbehorende complicaties) in belangrijke mate hoger ligt dan in 
omliggende landen. Tien verschillende dieren waren aangetast met seromas na 
keizersnede waaruit M. bovis werd geïsoleerd. Insertie sequentie typering wees aan dat 
de stam die werd geïsoleerd uit de seromas dezelfde was als deze die werd geïsoleerd uit 




andere predilectieplaatsen zoals de uier en de gewrichten, wat kan wijzen op een 
spreiding van de kiem van deze primaire sites naar het seroma. Dankzij stamtypering 
werd er ook een verband gezien tussen de overdracht van eenzelfde stam tussen twee 
bedrijven, en de mogelijke betrokkenheid van de dierenarts in deze verspreiding. 
Uit de studies vervat in deze thesis kan worden besloten dat M. bovis aanwezig is in een 
significant deel van de Belgische rundveebedrijven. Hoewel aankoop van dragerdieren de 
belangrijkste oorzaak van introductie is op nieuw geïnfecteerde bedrijven, moet de 
identificatie van de stier als een risicofactor voor het positief testen van TM en de 
identificatie van de dierenarts als mogelijke overdrager van de seroma vormende M. bovis 
stam ons aanmoedigen ook andere mogelijke oorzaken van spreiding te onderzoeken. 
Colostrum lijkt op basis van onze studie van minder belang te zijn in de overdracht van M. 
bovis binnen een reeds geïnfecteerde kudde, maar M. bovis DNA kan wel aanwezig zijn. De 
overdracht van M. bovis binnen een kudde door de stier of door de blootstelling van vee 
aan M. bovis rond het kalven (via uteriene secreties of tgv. immunosupressie) kunnen 
beide een mogelijke rol spelen in de epidemiologie van M. bovis, maar verder onderzoek 
om deze risicofactoren beter te begrijpen is noodzakelijk.  
Deze aanvullingen tot de epidemiologie van M. bovis kunnen dierenartsen en veehouders 
hopelijk helpen met het ontwikkelen van meer efficiënte preventie- en 
controleprogramma’s in de nabije toekomst, om de spreiding van deze kiem af te remmen. 
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“Aut viam inveniam – aut faciam”, de gevleugelde woorden op de vorige pagina en de 
lijfspreuk van mijn club, betekent zoveel als “ik zal een weg vinden, of ik zal er één maken”. 
Een doctoraat is exact dat: hard labeur en trachten een weg te banen naar het eindpunt: 
het doctoraat (of het beginpunt, het is hoe je het bekijkt…). Zoals dat lange wegen betaamt, 
zijn er vele mensen te danken die deze weg samen met mij hebben afgelegd of die ik 
onderweg tegenkwam en die (een stuk van) de weg met me meereisden.  
In de eerste plaats dien ik natuurlijk mijn promotoren te bedanken: First en foremost: 
Bart, bedankt voor de hulp, de steun en het vertrouwen de voorbije 4 jaar. Zonder jouw 
“aanmoediging”, of beter gezegd, schop onder de kont, was dit doctoraat er mogelijk nooit 
geweest. Bedankt voor het luisteren elke keer dat ik weer eens met rare vragen of ideeën 
kwam binnenvallen, het dubbel checken van diagnoses als ik weer eens aan mijn eigen 
kunnen twijfelde, en het vertrouwen dat je me gegeven hebt.  Ik heb nog steeds een 
communicatiecursus van je tegoed!  
Professor Deprez, ook U wil ik bedanken voor het vertrouwen. Zonder uw goedkeuren om 
me aan te houden als “Dehousse” bursaal was dit doctoraat er nooit kunnen komen. Uw 
kennis van de inwendige ziekten is legendarisch, en ik ben blij dat ik U zo nu en dan kon 
terugvinden op uw bureau als ik weer eens een bizarre case had binnengekregen om deze 
dan gezamenlijk te kunnen bespreken.  
Naast de promotoren in mijn eigen departement was er natuurlijk het bacteriologische 
deel van mijn promotoren team: Professor Haesebrouck, bedankt voor het enthousiasme 
in mijn project, de constructieve feedback en het steeds grondige nalezen en verbeteren 
van mijn papers en andere werken. Filip, ook jou dien ik te bedanken voor alle tijd die je 
in mij gestoken hebt, de aanmoedigingen als het wat lastig werd, en alle bacteriologische 
principes die je getracht hebt me bij te brengen. Verder op de bacteriologische dienst wil 
ik natuurlijk ook Marleen, Arlette en Serge bedanken voor het vele werk dat ze verzet 
hebben en de ondersteuning die ze me hebben geboden. Marleen, nog eens extra bedankt 
voor de race tegen de tijd eind 2017. Zonder jouw aanmoedigingen en werk was ik nooit 
in Zwitserland geraakt, en mijn stalen al helemaal niet! 
Op mijn eigen vakgroep waren er natuurlijk mijn collega’s van “Team Rund” (soms ook 
wel “Bart’s angels” genoemd). Laura, samen met jou begon ik aan dit avontuur na ons 
afstuderen, in de hoop een IWT-beurs te halen. Het eerste jaar faalden we beiden in dit 
opzet, gelukkig kon jij in het daaropvolgende jaar de beurs wel binnenhalen, met hopelijk 
dan ook volgend jaar de volkroning van jouw doctoraat! Merci voor elke keer dat ik weer 
bacteriologiestalen in je schoenen kon schuiven omdat ik geen zin had van tot “aan den 
overkant” te lopen, de memorabele feestjes in binnen- en buitenland, en de steun, zeker 
tijdens de laatste maanden! En ik kan het niet genoeg zeggen, RESPECT voor daarnaast 
ook nog eens eigenhandig jullie prachtige huis gebouwd te hebben tezelfdertijd!  
Lieze, eerst als intern, daarna als resident slaag je er steeds in een enorme berg werk te 
verzetten. Mede dankzij jouw extra inzet (samen met de andere mensen van team rund 
natuurlijk 😉) kon ik me de laatste maanden wat terugtrekken uit de kliniek om dit boekje 
te schrijven. Ik heb enorm respect ook voor je doorzettingsvermogen en weet dat dat 




kampen volgend jaar goed gaat komen, net zoals de residency! Hopelijk komen we elkaar 
nog veel tegen op allerhande workshops en dergelijke in de tussentijd, kunnen we nog 
eens bijbabbelen!  
Kath, ik heb enorm veel respect voor de manier waarop jij je op dingen kan gooien, en ben 
er zeker van dat ook jouw doctoraat binnen de kortste keren in de pocket gaat zijn! 
Bedankt voor de leuke babbels, de goede recepten, het lekkere eten, de inspirerende 
quotes en zeker voor de hilarische one-liners die zo nu en dan uit je mond kwamen! Dat 
ardennen-angus weekend moet er zeker komen! 
Jade, mijn co-Mycoplasma fanaat, jij bent de laatste toevoeging geweest aan het runder-
doctoraatsteam, maar zeker niet de minste daarvoor! Merci voor alle leuke momenten op 
en naast de kliniek, de babbels, de vriendschap en het mogen komen zeuren in je bureau 
als onze stomme bacterie weer maar eens tegenwerkte. Ik beloof dat de housewarming 
en rondleiding in Luik er snel komt, en hopelijk raken we beide in Tel Aviv 2020! 
Christien, soms wel eens de “oma” van team rund genoemd 😉. Ook de manier waarop jij 
je aan je doctoraat wijdt verdient niets dan bewondering. Ik mis de verhalen over de 
knollies, “de overkant” en je beste vriendin ELISA nu al!   
Bonnie, hoewel je al een tijdje niet meer op de faculteit bent, verdien je in mijn ogen toch 
nog steeds een ereplaats als lid van team rund. Als student vond ik je al een 
voorbeeldfiguur qua lesgeven en klinisch kunnen, en ook tijdens mijn loopbaan als 
kliniekdierenarts heb ik enorm veel van je geleerd. Merci, voor elke keer dat ik weer eens 
belde tijdens mijn wachten om raad te vragen!   
Karlijn, jij had de (al dan niet twijfelachtige) eer de eerste runderintern te zijn. Merci, voor 
al het zware werk dat je verzet hebt, en nogmaals proficiat met je huwelijk!  
Lisa, ook jij was een echte toegevoegde waarde voor ons runderteam met je “Deutsche 
Grundlichkeit”. Het lijkt je te bevallen daar in “het hoge noorden”, maar ik hoop dat je toch 
eens er in slaagt van op bezoek te komen 😉. Merci ook aan jou, voor alles! Mathilde en 
Charlotte, bedankt voor het schrijven van de verslagen die ik liet liggen, ik voel me er nog 
steeds schuldig over 😉. Ik wens jullie een super internship toe, voldoende stimulerend 
zonder dodelijk uitputtend te zijn! Mathilde, nog eens extra bedankt voor de babbels en 
zo nu en dan te zorgen dat ik nog eens buiten kwam de laatste maand van mijn doctoraat! 
Stijn, hoewel je Bart’s bureau alweer ontgroeid bent verdien je in mijn ogen toch ook een 
vermelding als member van team rund 😉.  
Naast “team rund” is er natuurlijk ook “team paard” op de vakgroep. Laurence, Gunther, 
Annelies, Dominique, Lisse, Glenn, Joke, Sofie, Ellen, Barbara, Lisa, Zoe, en alle interns van 
de voorbije jaren: bedankt voor de leuke samenwerking!  
Alex, wat begon als samen koken als we beiden van wacht waren draaide uit tot echte 
vriendschap en avonden “jani of temptation kijken” vanuit mijn zetel. “Jani wordt 
dierendokter” is en blijft het beste tv-concept that needs to happen. Merci voor elke keer 
dat je me vanachter mijn computer vandaan kwam halen als ik weer laat aan het 





van de eerste keer gaat halen! Barbara, Ellen, ook aan jullie veel succes toegewenst met 
studeren voor dat vervelende residency examen! 
Natuurlijk bestaat de vakgroep uit veel meer dan alleen dierenartsen, iedereen even 
essentieel voor het goede functioneren van de inwendige ziekten-machine. Hans, merci 
voor alles in goede banen te leiden beneden, de computer- en andere bijstand en het 
geduld met traag komende verslagen (en het melden wanneer er pralines beneden te 
vinden waren!). Sylvie, ook jij bedankt voor alles wat je doet achter en voor de schermen 
om de vakgroep te doen draaien! Sabrina, bedankt voor alle moeite die je gestoken hebt 
in het gieten van PAM platen, het analyseren van stalen en het maken van ELISA’s, je werk 
is echt onmisbaar voor de doctoraatsstudenten onder ons! Elvin: ook jij bedankt voor alles 
wat jij doet om de kliniek te laten draaien! Saar, Tony, Balder, Carlos en Julien: merci ook 
voor alle werk dat jullie verzetten!  
Ook iedereen van de andere vakgroepen, van medische beeldvorming tot aan 
buitenpraktijk, met wie ik in de laatste 4 jaar kon samenwerken op of naast kliniek 
verdient natuurlijk een enorme merci. Enkelen verdienden in mijn ogen toch een 
persoonlijke vermelding:  
Kirsten, eigenlijk heb jij ook een ereplaats in de rangen van “team rund”. Bedankt voor 
alle “projectjes” waar je, soms ondanks gezond verstand, je tanden inzette, de leuke 
momenten op- en naast de kliniek en de soms al dan niet bedoeld hilarische operaties. 
Hoewel ik onze gezamenlijke bad luck streak ook wel hardgrondig vervloekt heb als ik 
weer eens op de nek van een gecrashte halfwas dikbil zat om m tegen de grond te 
houden… Succes met je lama-doctoraat! Dat komt goed! Professor Vlaminck, Stijn, 
Thomas, Kelly, Michèle, Daphne, Anna, Lavinia, Elke, Charlotte en alle anderen van het 
heelkundige wachtteam: bedankt voor alle inzet tijdens de wachten! Leen, Laurien, 
Norbert, en alle anderen van het patho team: bedankt voor de geweldige samenwerking! 
Leen & Laurien: ook bedankt voor de leuke trainingen ’s middags! 
Een bijzondere bedanking is ook gepast voor het DGZ/veepeiler team met wie ik nauw 
kon samenwerken in mijn onderzoeken, op congressen en als deel van de RunderRadar. 
Merci, Jozefien, Stefaan, Koen, Evelien, Hans, en alle anderen! 
Zyncke, jij verdient een eigen alinea 😉. Ik had nooit gedacht 10 jaar geleden dat wij 
samen, bijna gelijktijdig, zouden doctoreren. Van de anatomie practica, over onze passage 
in Duitsland tot in Slovenië: de voorbije 10 jaar zijn het bewijs dat we, en onze 
vriendschap, alles aankunnen. Veel succes met de laatste loodjes van je doctoraat, veel 
plezier op je wereldreis (ik verwacht ten minste 3 postkaartjes!), en zie maar dat je (en 
Geert) heelhuids terugkomt.  
Anais, Anne, Annelot, Elisabeth en Katja : de « Leuven » gang, hoewel we elk onze eigen 
weg gaan (en zo nu en dan tot in de uithoeken van de planeet van elkaar verwijderd zijn), 
blijven we er in slagen onze vriendschap te onderhouden. Bedankt voor de mooie 
herinneringen (en deze die nog gaan volgen!) en de aanmoedigingen tijdens mijn hele 
doctoraatslijdensweg. Jullie zijn allemaal topwijven ;). Al mijn andere vrienden, in binnen 




en buitenland, diergeneeskundig of niet, zijn natuurlijk ook meer dan bedankt voor hun 
aanmoedigingen en steun. 
Een bijzondere groep in mijn vriendengroep zijn mijn sportvrienden. Toen ik mijn studies 
afgewerkt had en aan mijn doctoraat begon startte ik op goed geluk aan een sport, om 
eindelijk terug iets actiefs te doen: Shinkendo: Ben, Donna, Marnick, Sam, Geert, Luka, 
Andreas, David en de anderen: bedankt voor de leuke tijd, zowel in Gent als op de 
seminaries in Hongarije en elders!   
Vorig jaar vond ik dan echter de club die me het gevoel gaf thuis te komen, mijn 
verschrikkelijk politiek incorrecte mengelmoes die toch goed samengaat. Invirtus: 
bedankt voor alles, Jem, Jens, Jeroen, Robin, Tom, Joren, Ruben, Samuel, Nils, Kevin, 
Andrew en de rest of the gang 😉. PIM PAM PET! 
De mensen die me goed kennen weten dat mijn familie ook heel belangrijk voor me is. Bij 
deze wil ik dan ook ieder lid van mijn familie bedanken voor te zijn wie ze zijn, 
ongegeneerd, eerlijk, en oprecht. Onze familie heeft zijn verliezen gekend de laatste jaren, 
en ik wil jullie allemaal bedanken voor de steun die we aan elkaar hadden. Zeker ook mijn 
broers verdienen een bedankje voor de steun en het (hoewel soms eindige) geduld 😉.  
De belangrijkste persoon in mijn leven wordt als laatste bedankt. Mama, jij was er altijd 
voor me, ook als het/ik niet makkelijk was. Bedankt voor alles wat je voor mij gedaan hebt 
en nog steeds doet. Ik zeg het misschien niet vaak genoeg, maar ik ben trots je dochter te 
zijn, en ik ben er zeker van dat papa ook trots is.  
 
Iedereen, vanuit het diepste van mijn hart:  
Bedankt! 
 
 
 
